rawson cv june 10, 2017 - contentmanager.med.uvm.edu

Richard A. Rawson, Ph.D.

Curriculum Vitae June 10, 2017

PERSONAL HISTORY Address: 1952 Rte 73 Brandon, VT 05733 (310) 951-9091 mobile Citizenship: United States of America EDUCATION 1970 University of Vermont, Burlington, Vermont B.A., Psychology, University of Vermont 1974 University of Vermont, Burlington, Vermont Ph.D., Psychology PROFESSIONAL EXPERIENCE

2016 - Present Research Professor, Center for Behavior and Health, Department of Psychiatry, University of Vermont, Burlington Vermont

2016 - Present Professor Emeritus, Department of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles California

2012 – Present Adjunct Clinical Professor, Department of Psychiatry, University of Hawaii, Manoa, Honolulu, Hawaii

2013 – 2015 Co-Director, UCLA Integrated Substance Abuse Programs (ISAP), UCLA Department of Psychiatry and Biobehavioral Sciences, Los Angeles, CA.

2006 – 2015 Professor-in-Residence, UCLA Department of Psychiatry and Biobehavioral Science, Los Angeles, CA.

1995 – 2013 Associate Director, UCLA Integrated Substance Abuse Programs (ISAP), UCLA Department of Psychiatry and Biobehavioral Sciences, Los Angeles, CA.

1999 – 2006 Adjunct Associate Professor, UCLA Department of Psychiatry and Biobehavioral Science, Los Angeles, CA.

1996 – 2001 Director of Research, NIDA Medication Development Unit, Long Beach Veterans Affairs, Long Beach, CA.

1988 – 1998 Executive Director and Board Member, Matrix Institute on Addictions, Los Angeles, CA. 1984 – 1998 President and Chairman of the Board, Matrix Center, Los Angeles, CA. 1979 – 1984 Director of Operations, Community Health Projects, West Covina, CA. 1978 – 1980 Assistant Research Psychologist, Department of Psychiatry, New York Medical

College, NY. 1974 – 1978 Assistant Research Psychologist, Department of Psychiatry, UCLA, Los

Angeles, CA.

Richard A. Rawson, PhD

2

PROFESSIONAL ACTIVITIES Professional Associations and Committee Service

2015 Scientific Committee of the 20th World Congress of the World Federation for Mental Health (WFMH 2015) in Cairo, Egypt, Oct. 16-19, 2015.

2013 The American Friends of Skoun, Board of Directors 2013 Treatment Research Institute, Policy Advisory Council 2013 – 2015 UCLA Center for World Health, Internal Advisory Committee 2011– 2014 SAMHSA-HRSA Center for Integrated Health Solutions (CIHS) Advisory Committee

2010 – 2013 Betty Ford Institute, Executive Council 2007 – 2010 College on Problems of Drug Dependence (CPDD), Board of Directors

1987 – 2015 American Psychological Association (APA) 2001 – 2013 Advisory Group for Director of California Department of Alcohol and Drug Programs Editorial Services

2016-Present Executive Board and Editorial Board, International Addiction Review

2014 – Present Associate Editor, Journal of Studies on Alcohol and Drugs

2009 – Present Editorial Board, Journal of African Behavioral Health

2004 – 2007 Editorial Board, NIDA Science & Practice Perspectives 2001 – 2010 Associate Editor, Journal of Substance Abuse Treatment Continuous Ad hoc reviewer for numerous journals 2007 Guest Editor for Addiction special issue on Methamphetamine. 2003 Guest Editor for the Journal of Psychoactive Drugs special issue on California Policy Issues 2002 Guest Editor for the Journal of Drug Issues special issue on Practice-Research Integration 2002 Guest Editor for the Journal of Substance Abuse Treatment special issue on Blending Practice

and Research 2002 Guest Editor for the Journal of Addictive Diseases special issue on Methamphetamine 2000 Guest Editor for the Journal of Psychoactive Drugs special issue on Methamphetamine 1996 – 1999 Member of the Editorial Advisory Board for the CSAT Treatment Improvement Protocol

(TIPs) 1994 – 1998 Editorial Board for Journal of Maintenance in the Addictions 1993 – 1997 Editorial Board of Behavioral Healthcare Management Magazine International, Federal, and State Agency Activities

Member WHO Working Group on Mental Health Guidelines (ongoing) Member California Institute for Mental Health Integration Expert Panel, Jan. 9 & 10, 2012 Participant ONDCP/SAMHSA meeting on workforce development, July 2011 Member NIDA Ad Hoc IRG Committees (Multiple Occasions) Team Member NIDA Site Visit Grant Review (Multiple Occasions) Chair NIDA Ad Hoc Grant Review Sessions (Multiple Occasions) Member NIDA Technical Review Sessions, 1991 Consultant NIDA on the Development of Ibogaine, 1993 Participant Expert Panel for the House Committee on Technology Transfer, 1998 Participant First NIDA Conference on Technology Transfer, 1991 Consultant Attorney General Reno and ONDCP on Methamphetamine, 1996-2000 Member CSAT Expert Panels for Treatment Improvement Protocols (TIPS), 1995-2003 Member TIP Editorial Advisory Board to CSAT, 1995-2003 Testified U.S. Senate and House hearings on methamphetamine 2004, 2005, 2006 Speaker U.S. Department of State on methamphetamine. U.S. Embassy, Vienna, Austria,

2005


3

Member SAMHSA-sponsored training team to work with the Iraqi Health Ministry on substance abuse treatment, Cairo, Egypt, March 2006

Co-Chair Governor’s (California) Commission on Methamphetamine, 2006-2007 HONORS and SPECIAL AWARDS

2013 Dole and Nyswander Career Achievement Award, AATOD 2011 NIDA International 2011 Award of Excellence 2009 UCLA Department of Psychiatry Excellence in Teaching Award 2009 Decade Lecture at the ISAM Annual Meeting in Calgary, Canada 2007-2010 Elected to the Board of Directors of the College on Problems of Drug Dependence 2008 Outstanding Work in the Area of Research, County Alcohol and Drug Administrators’

Association of California 2008 CSAM Vernelle Fox Award Presentation 1998 Friends Research Institute Mentoring Award CURRENT RESEARCH, TRAINING and EVALUATION GRANTS and CONTRACTS

2017-Present Principal Investigator, Implementation of the California Hub and Spoke System of Opioid Treatment. California Department of Health Services. $2,000,000

2016-2017 Principal Investigator, Evaluation of the Vermont Hub-and-Spoke System for the Treatment of Opioid Use Disorders, Vermont Department of Health. $200,000

2012-2017 Co-principal Investigator, SBIRT for Substance Abuse in Mental Health Treatment Settings. Funded by National Institute on Drug Abuse, $2,500,000

COMPLETED RESEARCH, TRAINING AND EVALUATION PROJECTS

2014-Present Principal Investigator, Saudi Addiction Research Program; Ongoing variable contract. Saudi Embassy, Washington, DC

2014-2015 Principal Investigator, Cooperative Agreement for Workforce Development in Vietnam: HIV-Addiction Technology Transfer Center. $1,050,000

2012-2016 Principal Investigator, UCLA-Cairo University Training Grant, Funded by the NIH Fogarty Center, $1,100,000

2009-2015 Principal Investigator, Aerobic Exercise to Improve Outcomes for Treatment of Methamphetamine Dependence. Funded by National Institute on Drug Abuse. $2,400,000

2012-2015 Co-principal Investigator, Pacific Southwest Technology Transfer Center. $3,000,000. Funded by SAMHSA.

2012-2015 Principal Investigator, Evaluation of Skoun and Marsa Services in Beirut Lebanon. Funded by Drosos Foundation, $130,000

2013-2015 Principal Investigator, Iraqi National Drug Survey. Funded by State Department International Narcotic Liaison, CHS Subcontract $400,000.

2012-2014 Co-principal Investigator, Los Angeles County Evaluation Services, $2,200,000 2013-2014 Principal Investigator, SBIRT in Vietnamese HIV Treatment and Testing Centers.

NIDA Supplement, $100,000 1999-2015 Co-principal Investigator (Walter Ling, PI), Clinical Trials Network UCLA Node.

NIDA Grant to UCLA, $11,200,000. 2011-2014 Principal Investigator, Cooperative Agreement for Workforce Development in Vietnam:

HIV-Addiction Technology Transfer Center. $750,000. 2011-2012 Principal Investigator, Interagency Agreement to Provide Assistance to the Government

of Iraq’s Ministry of Health on Drug Demand Reduction. $1,000,000. 2012-2014 Co-principal Investigator, Evaluation Services and Technical Assistance Contract with

California Department of Alcohol and Drug Programs. $2,400,000 2009-2011 Principal Investigator, Evaluation Services to Enhance the Data Management System in

California. Funded by State of California/DADP. $1,800,000


4

2007-2012 Principal Investigator, NIDA Institutional Training Grant. $1,500,000. National Institute on Drug Abuse

2008-2010 Principal Investigator, Double-blind, Placebo Controlled Trial of Bupropion for Methamphetamine Dependence, NIDA Contract, $1,200,000.

2008-2010 Principal Investigator, Evaluation of the Co-occurring Disorders Court. $157,000. Funded by L.A County Department of Alcohol and Drug Programs.

2008-2009 Principal Investigator, Continuum of Services Redesign. $480,000. Funded by the State of California.

2007-2008 Co-principal Investigator, Training Contract to Improve Treatment for Individuals with Co-occurring Disorders $2,250.000. Funded by LA County Department of Mental Health, Thomas Freese, PI.

2007-2008 Principal Investigator, CARE Evaluation Contract. $250,000. Funded by the State of California.

2007-2008 Principal Investigator, California Outcomes Measurement System (CalOMS) Evaluation Contract. Funded by the State of California, $630,000.

2005-2007 Principal Investigator, Double-blind, Placebo Controlled Trial of Modafinil for Methamphetamine Dependence, NIDA Contract, $575,000.

2007-2011 Principal Investigator, LA County Evaluation System: An Outcomes Reporting Program (LACES), Phase III. Funded by the County of Los Angeles, California, $980,000.

2005-2007 Principal Investigator, Training and Capacity Building Center for the UNODC Worldwide Network of Substance Abuse Resource Centers. Funded by the UNODC, $480,000.

2005-2010 Co-principal Investigator, Four Models of Telephone Support for Stimulant Recovery, $2,585,197, NIDA, David Farabee, PI.

2005-2007 Co-principal Investigator, Children Endangered by Methamphetamine Use and Manufacture, NIDA, $387, 400, Nena Messina, PI.

2005-2010 Co-principal Investigator, Cognitive Behavioral Therapy for the Republic of South Africa, NIDA $1,487,500, Donnie Watson, PI.

2005-2009 Principal Investigator, UCLA Access to CARE Project, SAMHSA, $1,500,000. 2003-2005 Principal Investigator, Double-Blind, Placebo Controlled Study of Ondansetron for the

Treatment of Methamphetamine Dependence. UCLA ISAP, NIDA, Methamphetamine Clinical Trials Group, $500,000.

2002-2005 Principal Investigator, Double-Blind, Placebo Controlled Study of Bupropion for the Treatment of Methamphetamine Dependence. UCLA ISAP, NIDA, Methamphetamine Clinical Trials Group; NIDA $2,042,000.

2004-2005 Co-principal Investigator, Using Drug Abuse Research to Build Cooperation in the Middle East, $45,000, U.S. Institute of Peace, Darren Urada, PI.

2004-2007 Principal Investigator, Los Angeles County Evaluation System (LACES). Contract with LA County Office of Alcohol and Drug Programs, $950,000.

2003-2008 Principal Investigator, Methamphetamine Clinical Trials Group. A contract with NIDA, $8,000,000. Walter Ling, PI of Medication Development Services Master Contract.

2002-2003 Principal Investigator, Substance Abuse Research Training in South Africa, NIDA, $75,000.

2002-2007 Principal Investigator, Pacific Southwest Regional Addiction Technology Transfer Center (ATTC). Funded by CSAT, $2,200,000.

2002-2004 Principal Investigator, An Expansion of the Drug Abuse Early Warning System to include Data Collection in Egypt. U.S. Department of State: Middle East Regional Cooperative Grant to UCLA, $500,000.

2001-2003 Principal Investigator, A Drug Abuse Warning System for Israeli and Palestinian Communities. U.S. Department of State: Middle East Regional Cooperative Grant to Friends Research Institute, $500,000.

2001-2004 Co-principal Investigator. (Patricia Marinelli-Casey, PI) CSAT Methamphetamine Special Studies Contract $5,750,000.

2001-2006 Co-principal Investigator. (Barry Lester, PI) Prenatal Effects of Methamphetamine. NIDA Grant to Brown University with UCLA serving as a subcontractor for site coordination and data management. Subcontract, $880,000.


5

2000-2005 Principal Investigator, NIDA Methamphetamine Medication Network. Part of the NIDA Contract to UCLA Thomas Newton, Contract PI, $10,000,000.

2001-2004 Principal Investigator, CSAT Practice Improvement Collaborative (Phase 2), $1,042,000.

2000-2001 Co-Principal Investigator, (Natasha Brown, PI.) CSAT Practice Research Collaborative. (Phase 1) $200,000.

1999-2004 Co-Principal Investigator, (Michael Prendergast, PI) Application of Positive Contingencies in a Drug Court Setting. NIDA Grant to UCLA, $1,950,000.

1999-2001 Principal Investigator, Factors Influencing the Implementation of Naltrexone for the Treatment of Alcoholism. Robert Wood Johnson Foundation Grant to Friends Research Institute, $340,000.

1998-2003 Principal Investigator, Psychosocial Treatment Dose: A Prospective Evaluation. NIDA Grant to Friends Research Institute, $2,1400,000.

1999-2004 Co-principal Investigator (M.D. Anglin, PI), Los Angeles County Alcohol and Drug Program Outcome Project. Los Angeles County Contract with UCLA, $1,250,000.

1998-2001 Co-principal Investigator, Coordinating center for methamphetamine treatment project. A CSAT Grant to UCLA, $2,400,000.

1997-1998 Principal Investigator SCH 39166 for Cocaine Dependence and contract from Schering Plough awarded to Friends Research Institute, $350,000.

1997-1998 Principal Investigator, The implementation of LAAM: Factors affecting the use of a new opiate addiction treatment alternative. A Robert Wood Johnson Foundation grant awarded to Friends Research Institute, $203,906.

1997-2001 Co-principal Investigator, (A. Huber, PI) Medication/behavior therapy for methamphetamine abuse (1R01 DA10923). NIDA Grant, to Friends Research Institute, $1,788,253.

1997-1998 Co-principal Investigator, (S. Shoptaw, PI) Acamprosate for alcohol dependence. A contract from Lipha Pharmaceutical awarded to Friends Research Institute, $250,000.

1996-2000 Co-principal Investigator, (M.D. Anglin, PI) LAAM maintenance: HIV risk reduction potential and application. NIDA Grant, to UCLA DARC, $2,584,080.

1996-1999 Co-principal Investigator, (S. Shoptaw, PI) Contingency management-tobacco smoking in opiate addicts NIDA grant, Friends Research Institute, $709,802.

1995-1997 Co-principal Investigator, (S. Shoptaw, PI) A structured treatment manual for HIV+ substance abusers. NIDA, Small Business Innovative Research (SBIR), Phase II Grant to Matrix Center, $727,069.

1994-1999 Principal Investigator, Behavioral/Cognitive trial for cocaine abuse. NIDA Grant to Friends Medical Science Research, Inc. $1,939,653.

1993-1998 Co-principal Investigator, (Y. Hser, PI) Drug treatment counselors: Current practices and effectiveness. NIDA Grant to UCLA, $2,546,347.

1993-1994 Principal Investigator, Ritanserin for alcohol abuse. A contract from Janssen Foundation to Matrix Center, $350,000.

1992-1994 Principal Investigator, Ritanserin for cocaine abuse. A contract from Janssen Foundation to Matrix Center, $545,000.

1993-1994 Co-principal Investigator, (S. Shoptaw, PI) A structured treatment manual for HIV+ Substance Abusers. NIDA, Small Business Innovative Research (SBIR), Phase I Grant to Matrix Center, Inc. $72,453.

1991-1992 Principal Investigator, A rehabilitative framework for methadone treatment. A contract from the State of California to Matrix Institute, $125,000.

1991-1996 Co-Principal Investigator, (M D. Anglin, PI), UCLA center on treatment careers. NIDA Center grant to UCLA, $4,132,063.

1993-1995 Principal Investigator, A structured manual to facilitate naltrexone treatment. NIDA, Small Business Innovative Research (SBIR), Phase II Grant to Matrix Center, $472,600.

1991-1992 Principal Investigator, A structured manual to facilitate naltrexone treatment. NIDA, Small Business Innovative Research (SBIR), Phase I Grant to Matrix Center, $38,450.

1991 Principal Investigator, The Matrix model of alcoholism treatment. NIAAA, Small Business Innovative Research (SBIR), Phase I Grant to Matrix Center, $49,075.


6

1989-1994 Principal Investigator, Treatment of stimulant users to reduce HIV transmission. NIDA Research Demonstration Project to Friends Medical Research, Inc., $3,102,371.

1990-1992 Principal Investigator, A neurobehavioral model for outpatient cocaine addiction treatment. NIDA, SBIR Phase 2 Grant to Matrix Center, $499,075.

1988-1989 Principal Investigator, A neurobehavioral model for outpatient cocaine addiction treatment. NIDA, SBIR Phase 1 Grant to Matrix Center, $49,725.

1988-1991 Co-principal Investigator, (F. Castro, PI) Matches and mismatches in treatment for cocaine users. NIDA grant to San Diego State University, $450,000.

1985-1986 Principal Investigator, Lofexidine hydrochloride for methadone withdrawal. Merrill-Dow Contract, $40,000.

1980-1981 Principal Investigator, Clonidine hydrochloride for opiate detoxification. Boeringer Engelheim Contract, $50,000.

1978-1980 Project Director, Naltrexone and psychotherapy for opiate addiction. (R. Resnick, PI) NIDA grant to New York Medical College, $120,000.

1978-1981 Co-principal Investigator and Project Director. (R. Coombs, PI) "Social and familial components of combined use of alcohol and other drugs in a youthful population." State of California Office of Alcoholism Grant to UCLA, $200,000.

1978-1979 Co-principal Investigator and Project Director, (R. Coombs, PI) Family strengthening to redirect drug-prone youth. NIDA grant to UCLA, $600,000.

1974-1977 Co-principal Investigator and Project Director, (E.J. Callahan, PI) Heroin antagonist and learning therapy for opiate addiction. NIDA grant to UCLA, $525,000.

SELECTED LECTURES and PRESENTATIONS in the UNITED STATES (2005-PRESENT)

Dr. Rawson has conducted 10-50 presentations and workshops per year since 1985 throughout the United States and internationally. He also has provided consultation and training to state agencies, county agencies, treatment organizations, community organizations, public policy groups, and health and social service ministries for numerous countries. He has testified before the FDA, the California, Hawaii, Washington, Wyoming and Minnesota legislatures, and for several congressional committees. He is a frequent presenter at CPDD, ASAM, and APA conferences, as well as at NIDA, CSAT, ONDCP, WHO, and UNODC-sponsored training events. UNODC Treatnet Project: Dr. Rawson was the principal investigator for the training curriculum center for the United Nations Office on Drugs and Crime, Treatnet resource network. In this role, he was responsible for the design of an extensive package of training materials to be used as the core curriculum for a worldwide network of addiction training centers. Selected Presentations 2017 Clinton Foundation Healthcare Summit. Medication-Assisted Treatment for Opioid

Dependence: Rationale and Evidence of Effectiveness. Little Rock, Ark. April, 17, 2017. 2012–2016 Every year, I conducted 30–50 presentations/training sessions/workshops in the United

States (primarily, California). Topics include research on physical exercise, health system development, performance measures, cognitive behavioral strategies, use of screening and brief interventions, addiction medications, methamphetamine, research methods, and epidemiology of drug use in Iraq.

2011 CSAM Addiction Medicine State of the Art 2011 conference. Long Beach, CA. “Your Future Practice: Ingredients of Health Care Reform.” Oct. 12-15.

2011 Substance Use Disorders Treatment under Health Care Reform training. Hayward, CA. Oct. 3.

2011 CADPAAC Quarterly Meeting. Sacramento, CA. Sept. 28. 2011 National TASC Conference on Drugs and Crime. Denver, CO. “How the Affordable Care

Act will change the Treatment of Substance Use Disorders and How These Efforts will be Monitored, Measured and Evaluated.” May 4-6.

2011 CADPAAC meeting. Sacramento, CA. “EnCal Pilot Project Update.” March 22. 2011 Behavioral Health conference. Phoenix, AZ. “Developing Addiction Treatment Services

in Asia and the Middle East” and “Integrating Substance Use in Primary Care.” March 16, 19.


7

2011 Filming of: “Treating and Supervising Methamphetamine Addicts in Your Drug Court.” Williamsburg, VA. Jan. 23, 24.

2010 CATES Series Training. Alameda County, CA. “Substance Use Disorders Treatment under Health Care Reform: Welcome to the Health Care System.” Dec. 7.

2010 CATES Series Training. Merced County, CA. “Substance Use Disorders Treatment under Health Care Reform: Welcome to the Health Care System.” Dec. 1.

2010 CATES Series Training. Tehama County, CA. “Substance Use Disorders Treatment under Health Care Reform: Welcome to the Health Care System.” Nov. 17.

2010 Addictions 2010 Conference. Arlington, VA. “A Preliminary Examination of Client Transfers across Alcohol and Drug Treatment Services as a Measure of Provider Connectedness.” Oct. 30.

2010 ADP Training Conference. “Patient Perspectives on Medication-Assisted Opiate Addiction Treatment.” Sacramento.

2010 APA 118th Annual Convention. San Diego, CA. “How will Health Care Reform change Substance Use Disorder Treatment?” Aug.15.

2010 NADCP training. Jackson, MS. “Treating Meth Addicts in Your Drug Court.” Aug. 12, 13.

2010 72nd CPDD Conference. Scottsdale, AZ. “Preliminary Evidence on the Use of Aerobic Exercise in the Treatment of Methamphetamine Dependence.” June 17.

2010 NADCP 16th Annual Training Conference. Boston, MA. Update on the Methamphetamine Problem in the US. June 3.

2010 Hawaii Addictions Conference. Honolulu, HA. “A Passport over the Cultural Frontiers of Addiction” and “Next Journeys in Addiction Research.” March 17-19.

2010 Fresno Pilot Presentation on Addiction as a Chronic Health Problem. Fresno, CA. “Addiction as a Chronic Disease.” March 8.

2010 Betty Ford Center Grand Rounds “Addiction as a Chronic Disease” training. Rancho Mirage, CA. Feb. 18.

2010 Kern County Mental Health Conference. Kern County, CA. “Treatment of Methamphetamine Dependence: Clinical Challenges and Effective Strategies, Meth Update.” Feb. 1.

2010 CADPAAC. Sacramento, CA. Meeting. “EnCal Pilot Project Update.” Jan. 26-29. 2010 Treatment Strategies in Integrated Mental Health and Primary Care Services. San

Francisco, CA. Jan. 15. 2010 Cedars-Sinai Medical Center. Los Angeles, CA. “Methamphetamine Update: Is the

Epidemic Over?” Jan. 7. 2010 7th Annual Wyoming Methamphetamine and Substance Abuse Conference Agenda.

Casper, WY. “The Brain and Meth.” Jan 7. 2009 Medical University of South Carolina, 2009 AAAP Annual Meeting. Los Angeles, CA.

“Methamphetamine Use Disorders: Associated Symptoms and Treatment Options.” Dec. 6.

2009 8th Annual Conference: Jackson County Courts and Community: Caring for Children and Families; Families and Substance Abuse: Latest Knowledge and Interventions. Medford, OR. “Methamphetamine: Challenges for Human Service and Criminal Justice Professionals.” Nov. 20

2009 Treating and Supervising Methamphetamine Addicts in Your Drug Court. Omaha, NE. “Psychopharmacology; Treatment for Methamphetamine Addicts.” Nov. 10.

2009 Los Angeles Criminal Justice Inn of Court Meeting. Los Angeles, CA. “Addiction Changes the Brain: Implications for Treatment.” Nov. 4.

2009 2009 Addiction Health Support Research Conference: Health Care Reform, Parity and Continuing Care Models. San Francisco, CA. “Workshop for Substance Abuse Treatment Program Providers: Treating Addiction as a Chronic Condition: Rationale and Strategies to Extended Care.” Oct. 28-30

2009 UCLA’s 14th Annual Review of Psychiatry and Psychopharmacology Update. Los Angeles, CA. “Interventions for Substance Abuse: How to do them? Do they work?” Oct. 24.

2009 The Science of Drug Abuse in Schools and Colleges. Athens, GA. “Treatment for


8

Methamphetamine Dependence: Clinical Issues and Treatment Approaches.” Oct. 20. 2009 The University of Georgia. Athens, GA. “A Discussion of the Nation’s Current

Methamphetamine Problems.” Oct. 19 2009 Treating and Supervising Methamphetamine Addicts in Your Drug Court. Seattle, WA.

“Taking a Comprehensive Approach: Defining the Problem; Supervision and Behavior Modification for Meth Addicts, Manufacturing Trends.” Oct. 13

2009 The Substance Abuse Research Consortium 40th Semi-Annual Meeting. Sacramento, CA. “The National Quality Forum Report: The Foundation for Treatment Standards. Sept. 21.

2009 ADP Kick-Off COSSR meeting. Sacramento, CA.” Critical Components to a Continuum of Care.” Sept. 14.

2009 COSSR Program Presentation Fresno, CA. “Components of a Continuum of Care.” Sept. 1.

2009 Oregon’s Drug and Alcohol Prevention Programs Strategic Planning Meeting. Portland, OR. “Methamphetamine Dependence: Current Knowledge about Treatment.” Aug. 20.

2009 “Methamphetamine Dependence.” Berkeley, CA. Aug. 1. 2009 2009 Hawaiian Addictions Conference/AAPI Workgroup Scientific Conference on

Addiction and Related Issues. Honolulu, HA. “Building a Treatment System: Elements and Challenges.” May 11-12.

2009 NPI Clinical Leadership Forum. Los Angeles, CA. “Integrated Treatment of Co-occurring Disorders.” May 4.

2009 ASAM 40th Annual Medical-Scientific Conference. New Orleans, LA. “Cocaine and Methamphetamine Addiction: Clinical Update 2009.”April 30-May 2.

2009 ADP Continuum of Services Systems Re-Engineering meeting. “Key Components to a Continuum of Care.” Sacramento, CA. April 21-24.

2009 SSTAR training. Providence RI. “Methamphetamine Addiction: Basics of Treatment.” March 26-29.

2009 Region IX Health Care for the Homeless Conference. Los Angeles, CA. “Effective Drug Treatment Strategies for the Homeless.” Feb. 2.

2009 RPG Conference: Advancing Clinical and Collaborative Practice. Arlington, VA. “Methamphetamine and other Substances: Latest Knowledge, Latest Treatment.” Jan. 15.

2008 American Public Health Association Annual Meeting: Screening and Brief Intervention in a Mental Health Clinic: Public Health Agenda or Mental Health Therapy. San Diego, CA.

2008 SAMHSA: First National TC Conference: Set, Setting, and Dose: Critical Dimensions for Effective Criminal Justice TC Programs. Denver, CO

2008 SAMHSA: Updates on Methamphetamine: Effective Treatment and Other Hot Topics. Rockville, MD

2008 ADPA: Prescription Drugs Abuse: What are People Using and How Do You Treat Them? Alhambra, CA

2008 California Board of Parolee Trainings. Sacramento, Oakland, and Anaheim, CA 2008 Treatment of Methamphetamine Dependence: Strategies that Work, for the

Summer Conference for the Northwest Institute of Addiction Studies in Portland, Oregon

2008 Understanding Methamphetamine Addiction: New Knowledge from the Past Decade of Research, for the Summer Conference for the Northwest Institute of Addiction Studies in Portland, Oregon.

2008 CPDD. San Juan, Puerto Rico 2008 The ADP Conference 2008, Implementing a Comprehensive Continuum of Services:

Beyond Tradition - Creating Synergy. Burlingame, CA 2008 Annual Drug Court Conference. Los Angeles, CA 2008 UCSF Department of Psychiatry's New Developments in Substance Abuse Treatment

Grand Rounds. San Francisco, CA 2008 CADPAAC Quarterly Meeting. Sacramento, CA 2008 Methamphetamine: Modifications in Brain Functioning and Mental Health

Implications. Dallas, TX


9

2008 8th Annual California Information Management Conference and Exposition. Garden Grove, CA

2008 Medication-Assisted Treatment Training and Educational Symposium. Pleasant Hill, CA 2008 CalSWEC Mental Health Initiative Curriculum Infusion Seminar. Los Angeles, 2008

CCJCC Drug Court Coordinator Committee, Los Angeles, CA 2008 The 2008 Treatment Courts Training Day. Anaheim, CA 2008 MIA-STEP Phoenix House Training, OC (Part II). Santa Ana, CA 2008 The 10th Annual Fundamentals of Addiction Medicine. Seattle, WA 2008 Meth Task Force Meeting. Orange, CA 2008 Meth Task Force Meeting. Long Beach, CA 2008 5th Annual Methamphetamine and Substance Abuse Conference. Casper, Wyoming 2008 Evidence Based Treatments for Methamphetamine Dependence. Washington State

Legislature Event, Olympia, WA 2007 Society of Correctional Physicians (SCP) Meeting. Nashville, TN 2007 National Treatment Accountability for Safer Communities (NTASC) Annual Meeting.

Westminster, CO 2007 State of the Art 2007: Advancing the Clinical Practice of Addiction Treatments: Science

and Methodology, Culture and Society. Universal City, CA 2007 Treatnet: A Program to Increase Addiction Treatment Capacity Worldwide, SSTAR

Treatnet. Providence, Rhode Island. 2006 Methamphetamine in LA County: An Update. Alhambra, California 2006 Treatment for Methamphetamine-Related Disorders. Albuquerque, NM 2006 New Clinical Information Regarding the Treatment of Individuals for Cocaine and

Methamphetamine Dependence (CSAM) 2006 Methamphetamine: New Knowledge about the Epidemic, the Neurobiology and Clinical

Issues. Williamsburg, Virginia 2006 Treatments for Methamphetamine-Related Disorders. Williamsburg, Virginia 2006 Methamphetamine: Clinical Challenges and Critical Populations. Williamsburg, Virginia 2006 Methamphetamine: What Can Brain Imaging Tell Us? Williamsburg, Virginia 2006 Methamphetamine: Clinical Challenges and Critical Populations. Nashville, Tennessee 2006 Methamphetamine: The Nature of the National Epidemic. Nashville, Tennessee, 2006 Addiction as a Brain Disease: Blending Research and Practice to Enhance Prevention and

Treatment in YOUR Community. Sedona, Arizona 2005 Methamphetamine: A focus on women and children. Indianapolis, Indiana, 2005 Methamphetamine: How it influences the brain and behavior of users. Michigan 2005 Treatment for methamphetamine-related disorders: What works. Michigan 2005 Research Efforts in South Africa. UCSF, San Francisco. 2005 Methamphetamine: How it Influences the Brain and Behavior of Methamphetamine

Users. Sioux Falls, South Dakota 2005 Methamphetamine: Brain and Behavior-Research Findings. Sioux Falls, South Dakota 2005 Methamphetamine: A 2005 Update. Miami, Florida SELECTED INTERNATIONAL LECTURES and PRESENTATIONS (1997-PRESENT)

2012–Present Each year, I deliver 20–30 lectures, presentations, training sessions, workshops, etc., in UAE, Egypt, Vietnam, Saudi Arabia, Morocco, Iraq, and Iran. Topics include research on physical exercise, health system development, performance measures, cognitive behavioral strategies, use of screening and brief interventions, addiction medications, methamphetamine, research methods, and epidemiology of drug use in Iraq.

2013 Panel Chair, Addiction Service System Developments in Vietnam, International Society of Addiction Medicine, Kuala Lumpur, Malaysia, Nov 23.

2013 Invited Speaker, Methamphetamine, Pharmacology and Treatment, Training for Government Psychiatrists, arranged by U.S. Embassy, Ho Chi Minh Vietnam, April 8-9.

2013 Invited Speaker, Methamphetamine, Pharmacology and Treatment, Vietnamese National Institute of Mental Health, Hanoi, Vietnam, April 11-12.


10

2013 Invited Speaker, Methamphetamine Treatment and Treatment Priorities, NIDA SE Asia International Research Meeting, Taipei, Taiwan, April 17.

2013 Invited Speaker, Methamphetamine: Current Update on Research, Belgrade and Kraljevo, Serbia, April 23 and 27.

2013 Invited Speaker, Performance Measures in Addiction Treatment, Staffs of Skoun and Marsa organizations, Beirut, Lebanon, May 2.

2012 Co-Chair of Panel on Addiction Research from the Middle East, ISAM Annual Meeting, Geneva, Switzerland, Oct 14

2012 Invited Speaker, Current Research on Smoking Cessation, Jedda, Saudi Arabia, Oct 10 2012 Invited Speaker, Performance and Outcomes Measurement, Qassim Treatment Center,

Qassim, Saudi Arabia, Oct 9 2012 Invited Speaker, Contingency Management, Dammam Treatment Center, Dammam,

Saudi Arabia, Oct 6 2012 Invited Speaker, Development of a Program of Research on Addiction, Jazan University,

Jazan, Saudi Arabia, Oct 2. 2012 Invited Speaker, Performance and Outcomes Measurement, National Rehabilitation

Center, Abu Dhabi, UAE, Sept 25 2012 Grand Rounds, Baghdad Medical University, Baghdad, Iraq, May 11 2012 Member of the organizing committee and speaker at the Inaugural CEWG Meeting,

Baghdad, Iraq, May 8,9 2012 Invited Speaker, Matrix Model of Outpatient Treatment, National Rehabilitation Center,

Abu Dhabi, UAE April 29 2012 Lead Trainer, Iraqi Demand Reduction Project Clinical Training, Beirut, Lebanon, April

14-28 2012 Invited Speaker, First Annual Addictions Conference, Hanoi, Vietnam. March 7-12 2012 Invited Speaker, Cognitive Behavioral Therapy, Al Amal Hospital, Riyadh, Saudi Arabia,

Feb 25 2012 Member of Research Committee, Substance Abuse Research Center, Jazan University,

Jazan, Saudi Arabia, Feb 27-28. 2012 Lead Trainer, Iraqi Demand Reduction Project Clinical Training, Cairo Egypt Feb 1-21. 2011 Invited Speaker and faculty member at Cairo University Addiction Training Program,

Cairo, Egypt. Kasr Al-Ainy Conference. Cairo, Egypt. May 29-June 2 2011 Participant in UNODC Regional Meeting on ATS, Kumming, China 2011 Participant in Planning Meeting for first Vietnamese Annual Addiction Meeting, Hanoi,

Vietnam. April 13-22. 2011 Invited Speaker, 1st International Psychiatry Symposium. Riyadh, Saudi Arabia. Oct. 19-

20. 2010 ISAM 10th Annual Conference. Milan, Italy. “Dissemination and Implementation of

Cognitive Behavioural Therapy for Stimulant Dependence: A Comparison of Three Approaches.” Oct. 2-5.

2010 Invited Speaker, Methamphetamine Treatment XXVII CINP Congress. Hong Kong. June 6-10

2010 Invited Speaker, Kasr Al-Ainy International Psychiatry Conference. Cairo, Egypt. “Licensing Counselors and Psychotherapists in Egypt.” Feb. 20-27.

2009 Invited Speaker, Society for the Study of Addiction Annual Symposium. York, United Kingdom. “Treatment Policy.” Nov. 12.

2009 Invited Plenary Speaker, The International Society of Addiction Medication Anniversary meeting. Calgary, Alberta, Canada. “An Update on the Biopsychological Management of Stimulant Dependence.” Sept. 23-27

2009 Lead Trainer, UNODC: Drug Dependence Treatment and Care: Master Trainers Workshop. Vienna, Austria. May 24-28.

2009 Consultant, 4th Sino-US Training Program of Psychological Counseling and Therapy on Substance Dependence. Shanghai, China. April 4-12.

2009 Consultant, National Rehabilitation Center and International Society of Medicine. Abu Dhabi, UAE, and Cairo, Egypt. Feb. 10-23.

2009 Training Expert for Vietnamese Ministry of Health, Hanoi, Vietnam


11

2008 International Society of Addiction Medicine: Meth: New Knowledge. Cape Town, South Africa.

2008 International Society of Addiction Medicine Pre-Conference: Meth Treatment. Cape Town, South Africa

2008 First International Global Institute on Methamphetamine, Prague, Czech Republic 2008 Cracked but Not Broken Conference, Vancouver, BC 2008 Invited Speaker, International Society of Addiction Medicine, Cape Town, South Africa. 2008 Invited Speaker, World Methamphetamine Conference, Prague, Czech Republic. 2007 Conference Chair. Delivery Systems for Substance Abuse Treatment: Integration with

Primary Care and Mental Health and Social Services, Istanbul, Turkey Sept 3-6. 2007 Invited Speaker, Recent Advances in Methamphetamine Treatment, Vancouver, Canada. 2006 Invited Speaker: Bridges Have Been Built: Is Anyone Using Them? Amsterdam,

Netherlands 2006 Chair for the UNODC Treatnet Orientation, Cairo, Egypt. 2006 Invited Speaker, Advances in Addiction Treatment, Jeddah, Saudi Arabia. 2006 Methamphetamine and the Brain: New Knowledge; New Treatments, (US Embassy),

Vienna, Austria 2006 Invited Speaker, International Conference of Counselors in Addiction, Edinburgh,

Scotland. 2005 Invited Speaker, Methamphetamine: New Knowledge, United Nations Office of Drugs and

Crime, Vienna, Austria. 2005 Invited Speaker, Innovations in Substance Abuse Treatment, Beirut, Lebanon 2005 Invited Speaker, Recent Advances in the Integration of Substance Abuse Research and

Practice in the U.S. Radboud University, Nijmegen, Netherlands. 2005 Invited Speaker, Ministry of Health, Muscat, Oman. 2005 Methamphetamine: Brain and Behavior-Research Findings, Treatments for

Methamphetamine, Saskatoon, Saskatchewan 2004 Speaker at World Psychiatry Association Conference, Cairo, Egypt. 2004 Invited Speaker, Substance Abuse and Culture Conference, Vienna, Austria. 2004 Invited Speaker, World Health Organization, North Africa Region, Cairo, Egypt. 2004 Invited Speaker, United Nations Office on Drugs and Crime, Middle East Region, Cairo,

Egypt. 2004 Speaker at Grand Rounds, Ain Shams University, Cairo, Egypt 2004 Co-chair and Speaker, Delivery Systems for Substance Abuse Treatment conference,

Istanbul, Turkey. 2004 Invited Speaker, ISAM meeting, Helsinki, Finland. 2004 Invited Speaker, Ministry of Health, Bratislava, Slovakia. 2004 Speaker at Grand Rounds, Department of Psychiatry, University of Cairo, Egypt. 2004 Invited Speaker, First African Conference on Social Psychiatry, Johannesburg,

South Africa. 2003 Speaker at Grand Rounds, Department of Psychiatry, University of Cairo, Cairo, Egypt. 2003 Speaker at Grand Rounds, Department of Psychiatry, University of the Free State,

Bloemfountain, Republic of South Africa. 2003 Invited Speaker to the Israeli Society of Addiction Medicine, Tel Aviv, Israel. 2002 Invited Speaker to Addictions 2002 Conference in Amsterdam, Netherlands. 2002 Invited Speaker to the International Society of Addiction Medicine Meeting, Reykjavik,

Iceland. 2000, 2001 Trainer for U.S. Dept. of State on Stimulant Abuse Treatment, Bangkok, Thailand. 2000 Invited Speaker for the NIDA Conference on Methamphetamine, Budapest, Hungary. 2000 Invited Speaker on Addiction Pharmacotherapies, Amsterdam, Netherlands. 2000 Trainer for U.S. Department of State on Stimulant Abuse Treatment, Tijuana, Guadalajara,

and Mexico City. 1999, 2001 Invited Speaker at the U.S.-Mexico Bi-national Conferences on Substance Abuse Treatment, Mexico City, Mexico. 1999 Keynote Speaker on Research to Practice Issues, International Congress on Substance Abuse, Vienna, Austria.


12

1999 Invited Representative for NIDA on Substance Abuse Treatment at the U.S.-Netherlands Bi-National Substance Abuse Program. Amsterdam, Netherlands. 1997, 1998 Consultant to the Economic Cooperation Foundation (Oslo Peace

Accord Organizers) on Addiction Training in West Bank and Gaza, Palestinian Authority, weeklong addiction training at Al Quds University,

Ramallah, Palestinian Authority. 1997 Consultant to Swiss Government on Psychosocial Treatment Issues for

Substance Abuse Disorders, Thun, Switzerland. 1997 Invited Speaker. Addiction and Society, Presented for the Palestinian Authority Health

Committee, Arafat Health Center, Khan Younis, Gaza, November 1997 Keynote Speaker for Palestinian and Israeli People Against Substance

Use, Beersheva, Israel, November

BIBLIOGRAPHY RESEARCH PAPERS

A. RESEARCH PAPERS – PEER REVIEWED

1. Leitenberg, H., Rawson, R.A., & Bath, K. (1970). Reinforcement of competing behavior during extinction. Science, 169, 301-303.

2. Joffe, J.M., Rawson, R.A., Mulick, J.A., & Ley, K.F. (1972). Effects of adrenalectomy on open field behavior in rats. Hormones and Behavior, 3, 87-96.

3. Rawson, R.A., & Leitenberg, H. (1973). Reinforced alternative behavior during punishment and extinction with rats. Journal of Comparative and Physiological Psychology, 85, 593-600.

4. Leitenberg, H., Rawson, R.A., & Mulick, J.A. (1975). Extinction and reinforcement of alternative behavior. Journal of Comparative and Physiological Psychology, 88, 640-652.

5. Callahan, E.J., Rawson, R.A., Glazer, M., McLeave, B., & Arias, R. (1976). Comparison of two naltrexone treatment programs: Naltrexone alone versus naltrexone plus behavior therapy. In D. Julius & P. Renault (Eds.), Narcotic antagonist: Naltrexone progress report. NIDA Research Monograph, 150-157.

6. Mulick, J.A., Leitenberg, H., & Rawson, R.A. (1976). Alternative response training, Differential reinforcement of other behavior and extinction in squirrel monkeys. Journal of the Experimental Analysis of Behavior, 25, 311-320.

7. Rawson, R.A. Leitenberg, H., Mulick, J.A., & Lefebvre, M.F. (1977). Recovery of extinction responding in rats following discontinuation of reinforcement of alternative behavior: A test of two explanations. Animal Learning and Behavior, 5, 415-420.

8. Joffe, J.M., Mulick, J.A., Ley, K.F., & Rawson, R.A. (1978). Effects of prenatal stress procedures on maternal corticosterone levels and behavior during gestation. Bulletin of the Psychonomic Society, 11(2), 93-96.

9. Joffe, J.M., Rawson, R.A., & Mulick, J.A. (1973). Control of their environment reduces emotionality in rats. Science, 180, 1383-1384.

10. Washton, A.M., Resnick, R.B., & Rawson, R.A. (1979). Clonidine Hydrochloride: A non-opiate treatment for opiate withdrawal. Proceedings of the Committee on Problems of Drug Dependence. NIDA Research Monograph, 27, 233-239.

11. Rawson, R.A., Glazer, M., Callahan, E.J., & Liberman, R.B. (1979). Naltrexone and behavior therapy for heroin addiction. In N. Krasnegor (Ed.), Behavioral approaches to analysis and treatment of substance abuse. NIDA Research Monograph, June(25), 26-43.

12. Callahan, E.J., Rawson, R.A., McCleave, B., Arias, R., Glazer, M., & Liberman, R.P. (1980). The treatment of heroin addiction: Naltrexone alone and with behavior therapy. The International Journal of the Addictions, 15(6), 795-807.


13

13. Tennant, F.S., & Rawson, R.A. (1980). Heroin detoxification, Nurse Practitioner, 5, 35-39.

14. Washton, A.M., Resnick, R.B., & Rawson, R.A. (1980). Clonidine for opiate detoxification. Communication to Lancet, 1(8177), 1078-1079.

15. Tennant, F.S., Rawson, R.A., & McCann, M.J. (1981). Withdrawal from chronic phencyclidine (PCP) dependence with desipramine. American Journal of Psychiatry, 138, 845-847.

16. Tennant, F.S., & Rawson, R.A. (1981). Propoxyphene napsylate maintenance treatment for narcotic dependence: A non-methadone model. Drug and Alcohol Dependence, 8, 79-83.

17. Rawson, R.A., Tennant, F.S., & McCann, M.J. (1981). Characteristics of 68 chronic phencyclidine abusers who sought treatment. Drug and Alcohol Dependence, 8, 223-227.

18. Rawson, R.A., Mann, A.J., Tennant, F.S., & Clabough, D. (1982). Efficacy of psychotherapeutic counseling during 21 day ambulatory detoxification. Proceedings of the Committee on Problems of Drug Dependence. NIDA Research Monograph, 43, 310-314.

19. Tennant, F.S., & Rawson, R.A. (1982). Cocaine and amphetamine dependence treated with Desipramine. Proceedings of the Committee on Problems of Drug Dependence. NIDA Research Monograph, 43, 351-355.

20. Tennant, F.S., & Rawson, R.A. (1982). Outpatient treatment of prescription opioid dependence: Comparison of two methods. Archives of Internal Medicine, 142, 1845-1847.

21. Tennant, F.S., Rawson, R.A., Cohen, A.M., Tarver, A., & Clabough, D. (1983). Methadone plasma levels and persistent drug abuse in high dose maintenance patients. Substance and Alcohol Actions/Misuse, 4, 369-374.

22. Tennant, F.S., & Rawson, R.A. (1983). Guanabenz Acetate: A new long acting alpha-two adrenergic agonist for opioid withdrawal. Proceedings of the Committee on Problems of Drug Dependence. NIDA Research Monograph, 49, 338-343.

23. Rawson, R.A., Mann, A.J., Tennant, F.S., & Clabough, D. (1983). Efficacy of psychotherapeutic counseling during 21-day ambulatory heroin detoxification. Drug and Alcohol Dependence, 12, 197-200.

24. Tennant, F.S., Tarver, A., & Rawson, R.A. (1983). Clinical evaluation of mecamylamine for withdrawal from nicotine dependence. Proceedings of the Committee on Problems of Drug Dependence. NIDA Research Monograph, 49, 239-246.

25. Rawson, R.A., & Tennant, F.S. (1983). Five year follow-up of opiate addicts with naltrexone and behavior therapy. Proceedings of the Committee on Problems of Drug Dependence. NIDA Research Monograph, 49, 289-295.

26. Tennant, F.S., Rawson, R.A., Miranda, L., & Obert, J. (1983). Outpatient treatment of prescription opioid dependence: Comparison of two methods. Proceedings of the Committee on Problems of Drug Dependence. NIDA Research Monograph, 43, 315-321.

27. Tennant, F.S., Rawson, R.A., Cohen, A.M., Tarver, A., & Clabough, D. (1984). Methadone plasma levels and persistent drug abuse in high dose maintenance patients. Proceedings of the Committee on Problems of Drug Dependence. NIDA Research Monograph, 49, 262-265.

28. Rawson, R.A., Washton, A.M., Resnick, R.B., & Tennant, F.S. (1984). Clonidine hydrochloride detoxification from methadone treatment: The value of naltrexone aftercare. Advances in Drug and Alcohol Dependence, 3, 41-49.

29. Tennant, F.S., Rawson, R.A., Cohen, A.M., & Mann, A.J. (1984). Clinical experience with naltrexone in suburban opioid addicts. Journal of Clinical Psychiatry, 45, 42-45.

30. Rawson, R.A., Obert, J.L., McCann, M.J., & Mann, A.J. (1985). Cocaine treatment outcome: Cocaine use following inpatient, outpatient, and no treatment. Proceedings of the Committee on Problems of Drug Dependence. NIDA Research Monograph, 67, 271-277.

31. Rawson, R.A. (1986). Relapse prevention programming in the treatment of opioid users. Substance Abuse Bulletin, 2, 1-5.


14

32. Tennant, F.S., Rawson, R.A., Pumphrey, E.A., & Secoff, R. (1986). Clinical experiences with 959 opioid-dependent patients treated with levo-alpha-acetylmethadol (LAAM). Journal of Substance Abuse Treatment, 3, 195-202.

33. Baxter, L.R., Schwartz, J.M., Phelps, M.E., Mazziotta, J.C., Barrio, J., Rawson, R.A., Engel, J., Guze, B.H., Selin, C., & Sumida, R. (1988). Localization of the neurochemical effects of cocaine and other stimulants in the human brain. Journal of Clinical Psychiatry, 49, 23-26.

34. Rawson, R.A., Obert, J.L., McCann, M.J., Smith, D.P., & Ling, W. (1990). Neurobehavioral treatment for cocaine dependency. Journal of Psychoactive Drugs, 22(2),159-171.

35. Rawson, R.A. (1990). Cut the crack: The policymakers guide to cocaine treatment. Policy Review Journal, 51, 10-19.

36. Rawson, R.A., Obert, J.L., McCann, M.J., Castro, F.G., & Ling, W. (1991). Cocaine abuse treatment: A review of current strategies. Journal of Substance Abuse, 3, 457-491.

37. Rawson, R.A., Obert, J.L., McCann, M.J., & Ling, W. (1991). Psychological approaches for the treatment of cocaine dependence: A neurobehavioral approach. Journal of Addictive Diseases, 11(2), 97-119.

38. Rawson, R.A., & Ling, W. (1991). Opiate addiction treatment modalities and some guidelines for their optimal use. Journal of Psychoactive Drugs, 23(2), 151-163.

39. Rawson, R.A., Obert, J.L., McCann, M.J., Marinelli-Casey, P., & Suti, E. (1991). Outpatient chemical dependency treatment and the managed care system: An unrealized symbiosis. Journal of Ambulatory Care Management, 14(4), 48-59.

40. Rawson, R.A. (1990-1991). Chemical dependency treatment: The integration of the alcoholism and drug addiction/use systems. International Journal of the Addictions, 25(12A), 1515-1536.

41. Castro, F.G., Sharp, E.V., Barrington, E.H., Walton, M., & Rawson, R.A. (1991). Drug abuse and identity in Mexican Americans: Theoretical and empirical considerations. Hispanic Journal of Behavioral Sciences, 13(2), 209-225.

42. Castro, F.G., Barrington, E.H., Sharp, E.V., Dial, L.S., Wang, B., & Rawson, R.A. (1992). Behavioral and psychological profiles of cocaine users upon treatment entry: Ethnic comparison. Drugs and Society, 6, 231-251.

43. Ling, W., & Rawson, R.A. (1993). American opiate substitution treatment programs: From methadone to LAAM and Buprenorphine. Proceedings of the Swiss Services Project for the Medical Prescription of Narcotics. Thun, Switzerland.

44. Rawson, R.A., Obert, J.L., McCann, M.J., & Marinelli-Casey, P. (1993). Relapse prevention models for substance abuse treatment. Psychotherapy, 30(2), 284-298.

45. Rawson, R.A., Obert, J.L., McCann, M.J., & Marinelli-Casey, P. (1993). Relapse prevention strategies in outpatient substance abuse treatment. Psychology of Addictive Behaviors, 7(2), 85-95.

46. Rawson, R.A., Obert, J.L., McCann, M.J., & Ling, W. (1993). Neurobehavioral treatment for cocaine dependency: A preliminary evaluation. NIDA Research Monograph, 135, 92-115.

47. Harvey, E.M., Rawson, R.A., & Obert, J.L. (1994). History of sexual assault and the treatment of substance abuse disorders. Journal of Psychoactive Drugs, 26(4), 361-367.

48. Shoptaw, S., Rawson, R.A., McCann, M.J., & Obert, J.L. (1994). The Matrix Model of outpatient stimulant abuse treatment: Evidence of efficacy. Journal of Addictive Diseases, 13(4), 129-141.

49. Harvey, E.M., Rawson, R.A., Alexander, E., & Bacher, K. (1994). Binge eating in males: A sample description and treatment outcomes study. Eating disorders: Journal of Treatment and Prevention, 2(3), 215-230.

50. Grella, C.E., Anglin, M.D., Wugalter, S.E., Rawson, R.A., & Hasson, A. (1994). Reasons for discharge from methadone maintenance for addicts at high risk of HIV infection or transmission. Journal of Psychoactive Drugs, 26(2), 223-232.

51. Ling, W., Rawson, R.A., & Compton, M.A. (1994). Substitution pharmacotherapies for opiate addiction: From methadone to LAAM and buprenorphine. Journal of Psychoactive Drugs, 26(2), 119-127.


15

52. Rawson, R.A., McCann, M.J., Hasson, A., & Ling, W. (1994). Cocaine abuse among methadone maintenance patients: Are there effective treatment strategies? Journal of Psychoactive Drugs, 26(2), 129-136.

53. Hasson, A.L., Grella, C.E., & Rawson, R.A. (1994). Case management within a methadone maintenance program: A research demonstration project for HIV risk reduction. Journal of Case Management, 3(4), 167-172.

54. Rawson, R.A., Shoptaw, S.J., Obert, J.L., McCann, M.J., Hasson, A.L., Marinelli-Casey, P.J., Brethen, P.R., & Ling, W. (1995). An intensive outpatient approach for cocaine abuse treatment: The Matrix Model. The Journal of Substance Abuse Treatment, 12(2), 117-127

55. Frosch, D., Shoptaw, S., Huber, A., Rawson, R.A., & Ling, W. (1996). Sexual HIV risk among gay and bisexual male methamphetamine users. Journal of Substance Abuse Treatment, 13(6), 483-486. PMID: 9219145

56. McCann, M.J., Miotto, K., Rawson, R.A., Huber, A., Shoptaw, S., & Ling, W. (1996). Outpatient non-opioid detoxification for opioid withdrawal: Who is likely to benefit? American Journal on Addictions, 6(3), 218-223.

57. Shoptaw, S., Jarvik, M.E., Ling, W., & Rawson, R.A. (1996). Contingency management for tobacco smoking in methadone maintained opiate addicts. Addictive Behaviors, 21(3), 409-412.

58. Grella, C.E., Anglin, A.D., Rawson, R.A., Crowley, R., & Hasson, A. (1996). What happens when a demonstration project ends: Consequences for a clinic and its clients. Journal of Substance Abuse Treatment, 13(3), 249-256.

59. Johnson, B.A., Jasinski, D.R., Galloway, G., Kranzler, H., Weinrieb, R., Anton, R.F., Mason, B.J., Bohn, M.J., Pettinatti, H.M., Rawson, R.A., & Clyde, C. (1996). Ritanserin in the treatment of alcohol dependence: A multi-center clinical trial. Psychopharmacology, 128, 206-215.

60. Shoptaw, S., Frosch, D., Rawson, R.A., & Ling, W. (1997). Cocaine abuse counseling as HIV prevention. AIDS Education and Prevention, 9(6), 511-520. PMID 9451479

61. Obert, J.L., Rawson, R.A., & Miotto, K. (1997). Substance abuse treatment for "hazardous users": An early intervention. Journal of Psychoactive Drugs, 29, 291-298.

62. Miotto K., McCann M.J., Rawson R.A., Frosch D., Ling W. (1997). Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts. Drug and Alcohol Dependence, 45, 131-134.

63. Huber, A., Ling, W.L., Shoptaw, S., Gulati, V., Brethen, P, & Rawson, R. (1997). Integrating treatments for methamphetamine abuse: A psychosocial perspective. Journal of Addictive Diseases, 16(4), 41-50.

64. Frosch D., Shoptaw, S., Jarvik, M.E., Rawson, R.A., & Ling, W. (1998). Interest in smoking cessation among methadone maintained outpatients. Journal of Addictive Diseases, 17(2), 9-19.

65. Ling, W., Shoptaw, S., Wesson, D., Rawson, R.A., Compton, M., & Klett, C.J. (1998). Treatment effectiveness score as an outcome measure in clinical trials. NIDA Research Monograph, 175, 208-220.

66. Rawson, R., Hasson, A., Huber, A., McCann, M., & Ling, W. (1998). A 3-year progress report on the implementation of LAAM in the United States. Addiction, 93(4), 533-540.

67. Shoptaw, S., Reback, C.J., Frosch, D.L., & Rawson, R.A. (1998). Stimulant abuse treatment as HIV prevention. Journal of Addictive Diseases, 17(4), 19-32.

68. Gonzalez Castro, F., Barrington, E.H., Walton, M.A. & Rawson, R.A. (2000). Cocaine and methamphetamine: Differential addiction rates. Psychology of Addictive Behaviors, 14(4), 390-396.

69. Rawson, R.A., McCann, M.J., Hasson, A., & Ling, W. (2000). Addiction pharmacotherapy 2000: New options and new challenges. Journal of Psychoactive Drugs, 32, 371-378.

70. Domier, C.P., Simon, S.L., Rawson, R.A., Huber, A., & Ling, W. (2000). A comparison of injecting non-injecting methamphetamine users. Journal of Psychoactive Drugs, 32, 229-232.

71. Huber, A., Lord, R., Gulati, V., Marinelli-Casey, P., Rawson, R. & Ling, W. (2000). The CSAT Methamphetamine Treatment Project: Research design accommodations for “real world” application. Journal of Psychoactive Drugs, 32, 149-156.

72. Rawson, R.A., Huber, A., Brethen, P.B., Obert, J.L., Gulati, V., Shoptaw, S., & Ling,W. (2000). Methamphetamine and cocaine users: Differences in characteristics and treatment retention. Journal of Psychoactive Drugs, 32, 233-238.


16

73. Anglin, M.D., & Rawson, R.A. (2000). The CSAT Methamphetamine Treatment Project: What are we trying to accomplish? Journal of Psychoactive Drugs, 32, 209-210.

74. Rawson, R.A., McCann, M.J, Huber, A., Marinelli-Casey, P., & Williams, L. (2000). Moving research into community settings in the CSAT Methamphetamine Treatment Project: The coordinating center perspective. Journal of Psychoactive Drugs, 32(2), 201-208.

75. Shoptaw, S., Stein, J., & Rawson, R.A. (2000). Burnout in substance abuse counselors: Impact of environment, attitudes and clients with HIV. Journal of Substance Abuse Treatment, 19, 117-126.

76. Obert, J.L., McCann, M.J., Marinelli-Casey, P., Weiner, A., Minsky, S., Brethen, P., & Rawson, R.A. (2000). The Matrix Model of outpatient substance abuse treatment: History and description. Journal of Psychoactive Drugs, 32(2), 157-164.

77. Simon, S.L., Domier, C., Carnell, J., Brethen, P., Rawson, R.A., & Ling, W. (2000). Cognitive impairment in individuals currently using methamphetamine. American Journal on Addictions, 9(3), 222-231.

78. Blackwell, B., Nace, D., Rawson, R., Greenberg, P., Shaffer, I., Rofman, E.S., Callahan, J., Mee-Lee, D., Kasser, C., Miller, M.M., & Radcliffe, A. (2000.) Practice guidelines: An ASAM-AMBHA joint statement. Journal of Addictive Diseases, 19(2), 117-119.

79. Anglin, M.D., & Rawson, R.A. (Eds.) (2000). The CSAT Methamphetamine Treatment Project: Moving research into the “real world.” Journal of Psychoactive Drugs, 32(2), 135-136.

80. Rawson, R.A., McCann, M.J., Shoptaw, S., Miotto, K., Frosch, D.L., Obert, J.L., & Ling, W. (2001). Naltrexone for opiate addiction: Evaluation of a manualized psychosocial protocol to enhance treatment response. Drug and Alcohol Review, 20, 67-80.

81. Ling, W., Huber, A., & Rawson, R.A. (2001). New trends in opiate pharmacotherapy: A review. . Drug and Alcohol Review, 20, 51-68.

82. Isralowitz, R., Sussman, G., Afifi, M. Rawson, R., Babor, T., & Monteiro, M. (2001). Substance abuse policy and peace in the Middle East: A Palestinian and Israeli Partnership. Addiction, 96, 973-980

83. Burden, W., Prendergast, M., Roll, J., & Rawson, R.A. (2001). The role of contingency management in drug courts. Journal of Drug Issues, 31, 73-90.

84. Sim, T., Simon, S., Domier, C.P., Richardson, K., Rawson, R.A., & Ling, W. (2002). Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology. Journal of Addictive Diseases, 21(1), 75-89.

85. Simon, S.L., Richardson, K., Dacey, J., Glynn, S., Domier, C., Rawson, R.A., & Ling, W. (2002). A comparison of patterns of methamphetamine and cocaine use. Journal of Addictive Diseases, 21(1), 35-44.

86. Rawson, R.A., Huber, A., Brethen, P., Obert, J.L., Gulati, V., Shoptaw, S., & Ling, W. (2002). Status of methamphetamine users 2-5 years after outpatient treatment. Journal of Addictive Diseases 21, 107-119.

87. Rawson, R.A., Anglin, M.D., & Ling, W. (2002). Will the methamphetamine problem go away? Journal of Addictive Diseases 21, 5-19.

88. Miotto, K., McCann, M.J., Basch, J., Rawson, R.A., & Ling, W. (2002) Naltrexone and dysphoria: Fact or myth? American Journal on Addictions, 11(2), 151-160.

89. Marinelli-Casey, P.J., Domier, C. & Rawson, R.A. (2002). The gap between research and practice in substance abuse treatment. Psychiatric Services 53(8), 984-987.

90. Rawson, R.A., Washton, A.M., Domier, C.P., & Reiber, C. (2002). Drugs and sexual effects: Role of drug type and gender. Journal of Substance Abuse Treatment 22(2), 103-108.

91. Shoptaw, S., Rotheram-Fuller, E., Yang, X., Frosch, D., Nahom, D., Jarvik, M.E., Rawson, R.A., & Ling, W. (2002). Smoking cessation in methadone maintenance. Addiction, 97(10), 1317-1328.

92. Reiber, C., Ramirez, A., Parent, D., & Rawson, R.A. (2002). Predicting treatment success at multiple timepoints in diverse patient populations of cocaine dependent individuals. Drug and Alcohol Dependence, 68, 35-48.


17

93. McNeese-Smith, D., Crook M.W., Marinelli-Casey, P., Williams, L., & Rawson, R. (2002). Benefit determination under managed care for substance abuse treatment clients. Care Management Journals, 3, 55-62.

94. Rawson, R.A., Marinelli-Casey, P., & Ling, W. (2002). Dancing with strangers: Will U.S. substance abuse practice and research organizations build mutually productive relationships? Addictive Behaviors, 27(6), 941-950.

95. Rawson, R.A., Gonzales, R.G., & Brethen, P. (2002). Methamphetamine: Current research findings and clinical challenges. Journal of Substance Abuse Treatment 23, 145-150.

96. Rawson, R.A., & Stein, J. (2002). Blending clinical practice and research: Forging partnerships to enhance drug addiction treatment. Journal of Substance Abuse Treatment, 23, 67-68.

97. Spear, S., & Rawson, R.A. (2002). Linking substance abuse researchers and practitioners in the substance abuse field: Perspectives of two bridgers. Journal of Drug Issues, 32, 881-892.

98. Rawson, R.A. & Branch, C. (2002). Connecting substance abuse treatment and research: “Let’s make a deal.” Journal of Drug Issues, 32, 769-782.

99. Crevecoeur, D., Finnerty, B., & Rawson, R. (2002) The Los Angeles County Evaluation System (LACES): A large scale substance abuse treatment system evaluation program. Journal of Drug Issues, 32, 865-880.

100. Spear, S.A., & Rawson, R.A. (2002). Preface: Perspectives from the conference, “Common Ground, Common Goals, Common Language: Bringing Substance Abuse Practice and Research Together. Journal of Drug Issues, 32, 751-756.

101. Obert, J.L., London, E.D., & Rawson, R.A (2002). Incorporating brain research findings into standard treatment: An example using the Matrix Model. Journal of Substance Abuse Treatment, 23, 107-114.

102. Foreman, R., Dackis, C., & Rawson, R. (2002). Substance abuse: Twelve principles to more effective outpatient treatment. Current Psychiatry, 1, 16-24.

103. Rawson, R.A., Marinelli-Casey, P., & Huber, A. (2002). Treating methamphetamine dependence in adults. In R. Straw & J.M. Herrell (Eds.), Conducting multiple site evaluations in real world settings. New Directions in Evaluation, 94, 73-87.

104. Farabee, D., Rawson, R.A., & McCann, M. (2002). Adoption of drug avoidance activities among patients in contingency management and cognitive-behavioral treatments. Journal of Substance Abuse Treatment, 23, 343-350.

105. Rawson, R.A., Huber, A., McCann, M.J, Shoptaw, S., Farabee, D., Reiber, C., & Ling, W. (2002). A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Archives of General Psychiatry, 59(9), 817-824.

106. Miotto, K., Darakjian, J., Basch, J., Murray, S., Zogg, J., & Rawson, R.A. (2002). Gamma-hydroxybutric Acid (GHB): Patterns of use, effects and withdrawal. American Journal on Addictions, 10(3), 232-241.

107. Stizer, M.L., Owen, P.L., Hall, S.M., Rawson, R.A., & Petry, N.M. (2003). CPDD policy statement. Standards for drug abuse treatment providers. Drug and Alcohol Dependence, 71, 213-215.

108. Messina, N., Farabee, D., & Rawson, R. (2003). Treatment responsivity of cocaine-dependent patients with antisocial personality disorder in cognitive behavioral and contingency management interventions. Journal of Consulting and Clinical Psychology, 71,320-329.

109. McNeese-Smith, D.K., Crook, M.W., Marinelli-Casey, P., & Rawson, R.A. (2003). Processes and outcomes of substance abuse treatment within managed care: A preliminary report. Journal of Addictions Nursing, 14, 65-73.

110. Ling, W., Rawson, R.A., & Compton, M. (2003). Clinical treatment of opioid addiction and dependence. Methods in Molecular Medicine, 84, 285-295.


18

111. Watson, D.W., Rawson, R.A., Rataemane, S., Shafer, M.S., Obert, J.L., Bisesi, L., Tanamly, S. (2004). A distance education model for teaching substance abuse providers in cognitive behavioral therapy. Journal of Teaching in the Addictions, 2, 45-57.

112. Simon, S.L., Dacey, J., Glynn, S. , Rawson, R.A., & Ling, W. (2004). The effect of relapse on cognition in abstinent methamphetamine users. Journal of Substance Abuse Treatment, 27, 59-66.

113. Rawson, R.A., Marinelli-Casey, P., Anglin, M.D., Dickow, A., Frazier, Y., Gallagher, C., Galloway, G.P., Herrell, J., Huber, A., McCann, M.J., Obert, J., Pennell, S., Reiber, C., Vandersloot, D., Zweben, J., and the Methamphetamine Treatment Project Corporate Authors. (2004). A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction, 99, 708-717.

114. Ling, W., Cunningham-Rathner, J., & Rawson, R.A. (2004). Diffusion of substance abuse treatment: Will buprenorphine be a success? Journal of Psychoactive Drugs, May(Suppl. 2), 115-117.

115. London, E.D., Simon, S.L., Berman, S.M., Mandelkern, M.A., Lichtman, A.M., Bramen, J., Shinn, A.K., Miotto, K., Learn, J., Dong, Y., Matochik, J.A., Kurian, V., Newton, T., Woods, R., Rawson, R.A., & Ling, W.L. (2004). Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Archives of General Psychiatry, 61,73-84.

116. Shoptaw, S., Watson, D.W., Reiber, C., Rawson, R.A., Montgomery, M.A., Majewska, M.D., & Ling, W. (2005). Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). Addiction, 100(Suppl. 1), 78-90.

117. Brown, A.H., Domier, C., & Rawson, R. (2005). Stimulants, sex, and gender. Sexual Addiction and Compulsivity, 12, 169-180.

118. Longshore, D., Anglin, D., Annon, J., & Rawson, R.A. (2005). Levo-alpha-acetylmethyadol (LAAM) vs methadone: Treatment retention and opiate use. Addiction. 100, 1131-1139

119. London, E.D., Berman, S., Voytek, B., Simon, S.L., Mandelkern, M.A., Monterrosso, J., Thompson, P., Brody, A., Gaega, J., Hong, M., Hayashi, K., Rawson, R.A., & Ling, W. (2005). Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine users. Biological Psychiatry, 58, 770-778.

120. Spear, S., Hamilton, A., & Rawson, RA. (2005). Painting a picture of the client: Implementing the ASI in community treatment programs. Journal of Substance Abuse Treatment, 29, 277-282.

121. Rawson, R.A., Gonzales, R., Obert, J.L., McCann, M.J., & Brethen, P. (2005). Methamphetamine use among treatment-seeking adolescents in Southern California: Participant characteristics and treatment response. Journal of Substance Abuse Treatment, 29(2), 67-74.

122. Rawson, R.A., McCann, M.J., Flammino, F., Shoptaw, S., Miotto, K., Reiber, C., & Ling, W. (2006). A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction, 101(2), 267-74.

123. Hser, Y.I., Stark, M.E., Paredes, A., Huang, D., Anglin, M.D., & Rawson, R.A. (2006). A 12-year follow-up of a treated cocaine-dependent sample. Journal of Substance Abuse Treatment, 30, 219-226.

124. Isralowitz, R., & Rawson, R. (2006). Gender differences in prevalence of drug use among high risk adolescents in Israel. Addictive Behaviors, 31, 355-358.

125. Rawson, R.A., Gonzales, R., & Ling, W. (2006) Methamphetamine abuse and dependence: An update. New Directions in Psychiatry, 26, 221-236.

126. Gonzales, R.G., Marinelli-Casey, P.M., Shoptaw, S., Ang, A., & Rawson, R.A. (2006). Hepatitis C virus infection among methamphetamine dependent individuals in outpatient treatment. Journal of Substance Abuse Treatment, 31, 195-202.

127. Venneman, S., Leuchter, A., Bartzokis, G., Beckson, M., Simon, S.L., Schaefer, M., Rawson, R., Newton, T., Cook, I.A., Uijtdehaage, S., & Ling W. (2006). Variation in neurophysiological function and evidence of quantitative electroencephalogram discordance: Predicting cocaine-dependent treatment attrition. Journal of Neuropsychiatry and Clinical Neuroscience, 18, 208-216.


19

128. Ling, W., Rawson, R.A., & Shoptaw, S. (2006) Management of methamphetamine abuse and dependence. Current Psychiatry Reports, 8, 345-354.

129. Anglin, M.D., Urada, D., Brecht, M.L., Hawken, A., Rawson, R., & Longshore, D. (2007). Criminal justice treatment admissions for methamphetamine use in California: A focus on Proposition 36. Journal of Psychoactive Drugs, Suppl. 4, 367-381.

130. Castro, F., Rawson, R.A., & Stamper, E. (2007). Response: TIPsters weigh in: Putting good science to work. Science & Practice Perspectives, 3(2),35-36. PMCID: PMC2851078

131. Spear, S., Crèvecoeur, D.A., Rawson, R.A., & Clark, R. (2007). The rise in methamphetamine use among American Indians in Los Angeles County. American Indian and Alaska Native Mental Health Research, 14(2), 1-15.

132. Rawson, R.A., & Rutkowski, B.A. (2007, October 11). Prime numbers: A matter of life or meth. Foreign Policy, 163, 32-33.

133. Rawson, R.A., & Condon, T., (2007). Why do we need a special issue of Addiction focused on methamphetamine? Addiction, 102, 1-4.

134. Rutkowski, B., Freese, T., & Rawson, R. (2007). Editors’ introduction: California Substance Abuse Research Consortium 2006. Journal of Psychoactive Drugs, SARC Supplement 4, 309-311.

135. Rawson, R.A., Gonzales, R., McCann, M., & Ling, W. (2007). Use of methamphetamine by young people: Is there reason for concern? Addiction, 102(7), 1021-1022.

136. Rawson, R., Gonzales, R., Marinelli-Casey, P., & Ang, A. (2007). Methamphetamine dependence: A closer look at treatment response and clinical characteristics associated with route of administration in outpatient treatment. American Journal on Addictions, 16(4), 291-299.

137. Rawson, R.A., Maxwell, J., & Rutkowski, B. (2007). OxyContin abuse: Who are the users? American Journal of Psychiatry, 164(11), 1634-1636.

138. Messina, N., Farabee, D., & Rawson, R. (2007). Cocaine-dependent patients with antisocial personality disorder. Journal of Drug Addiction, Education and Eradication, 3(1/2), 75-96.

139. Isralowitz, R., Reznik, A., Spear, S., Brecht, M.L., & Rawson, R.(2007) Severity of heroin use in Israel: Comparisons between native Israelis and former Soviet Union immigrants. Addiction, 102, 630-637.

140. Hillhouse, M., Marinelli-Casey, P. Gonzales, R., Ang, A., & Rawson, R.A., & the Methamphetamine Treatment Project Corporate Authors. (2007). Predicting in-treatment performance and post-treatment outcomes in methamphetamine users. Addiction, 102, 84-95.

141. Elkashef, A.M., Rawson, R.A., Anderson, A.L., Li, S.-H., Holmes, T., Smith, E.V., Chiang, N., Kahn, R., Vocci, F., Ling, W., Pearce, V.J., McCann, M., Campbell, J., Gorodetzky, C., Haning, W., Carlton, B., Mawhinney, J., & Weis, D. (2007). Buproprion for the treatment of methamphetamine dependence. Neuropsychopharmacology, 33(5), 1162-1170.

142. Elkashef, A., Rawson R.A., Smith, E., Pearce, V., Flammino, F., Campbell, J., Donovick, R. Gorodetsky, C., Haning, W., Mahwinney, J., McCann, M., Weis, D., Williams, L., Ling, W., & Vocci, F. (2007). The NIDA Methamphetamine Clinical Trials Group: A strategy to increase clinical trials research capacity. Addiction, 102, 107-113.

143. Crevecoeur, D., Rutkowski, B., & Rawson, R. (2007). The rise in treatment admissions for methamphetamine use in Los Angeles County from 2001 through 2005. Journal of Psychoactive Drugs, SARC Supplement 4, 383-392.]

144. Rawson, R., Gonzales, R., Pearce, V., Ang, A., Marinelli-Casey, P., Brummer, J., and the Methamphetamine Treatment Project Corporate Authors. (2008). Methamphetamine dependence and human immunodeficiency virus. Journal of Substance Abuse Treatment, 35, 279-284. PMCID: PMC2630179

145. Messina, N., Marinelli-Casey, P., Hillhouse, M., Hunter, J., & Rawson, R. (2008). Childhood adverse events and health outcomes among methamphetamine-dependent men and women. International Journal of Mental Health and Addiction, 6(4), 522-536.


20

146. Marinelli-Casey, P., Gonzales, R., Hillhouse, M., Ang, A., Zweben, J., Cohen, J., Fulton Hora P., Rawson, R.A., and the Methamphetamine Treatment Project Corporate Authors (2008). Drug court treatment for methamphetamine dependence: Treatment response and post-treatment outcomes. Journal of Substance Abuse Treatment, 34(2), 242-248. PMID: 17596903

147. Gonzales, R., Ang, A., McCann, M., & Rawson, R. (2008). An emerging problem: Methamphetamine use among treatment seeking youth. Substance Abuse, 29(2), 71-80. PMID: 19042326

148. Lee, N.K., & Rawson, R.A. (2008). A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug and Alcohol Review, 27(3), 309-317. PMCID: PMC 4445690

149. Khalil, A., Okasha, T., Shawky, M., Haroon, A, Elhabiby, M., Carise, D., Annon, J.J., Hasson, A.M., Rawson, R.A. (2008). Characterization of substance abuse patients presenting for treatment at a university psychiatric hospital in Cairo, Egypt. Addictive Disorders and Their Treatment, 7(4), 199-209.

150. Glasner-Edwards, S., Mooney, L.J., Marinelli-Casey, P., Hillhouse, M., Ang, A., & Rawson, R.; the Methamphetamine Treatment Project Corporate Authors. (2008). Identifying methamphetamine users at risk for major depressive disorder: Findings from the Methamphetamine Treatment Project at three-year follow-up. American Journal on Addictions, 17(2), 99-102. PMID: 18393051

151. Glasner-Edwards, S., Mooney, L.J., Marinelli-Casey, P., Hillhouse, M., Ang, A., & Rawson, R., the Methamphetamine Treatment Project Corporate Authors. (2008). Risk factors for suicide attempts in methamphetamine-dependent patients. American Journal on Addictions, 17(1), 24-27. PMID: 18214719

152. Glasner-Edwards, S., Mooney, L.J., Marinelli-Casey, P., Hillhouse, M., Ang, A., Rawson, R.; the Methamphetamine Treatment Project Corporate Authors. (2008). Clinical course and outcomes of methamphetamine-dependent adults with psychosis. Journal of Substance Abuse Treatment, 35(4), 445-450. PMID: 18294802

153. Messina, N., Marinelli-Casey, P., Hillhouse, M., Rawson, R., Hunter, J., & Ang, A. (2008). Childhood adverse events and methamphetamine use among men and women. The Journal of Psychoactive Drugs, Suppl. 5, 399-409. PMID: 19248397

154. Rutkowski, B., Freese, T., & Rawson, R. (2008). Editors' introduction: California Substance Abuse Research Consortium, 2007: A focus on women. Journal of Psychoactive Drugs, Suppl. 5, 321-323. PMID: 19248391

155. Glasner-Edwards, S., Marinelli-Casey, P., Hillhouse, M., Ang, A., Mooney, L.J., & Rawson, R.; Methamphetamine Treatment Project Corporate Authors. (2009). Depression among methamphetamine users: Association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. Journal of Nervous and Mental Disease, 197(4), 225-231. PMCID: PMC2749575

156. Gonzales, R., Ang, A., Marinelli-Casey, P., Glik, D.C., Iguchi, M.Y., & Rawson, R.A.; Methamphetamine Treatment Project Corporate Authors. (2009). Health-related quality of life trajectories of methamphetamine-dependent individuals as a function of treatment completion and continued care over a 1-year period. Journal of Substance Abuse Treatment, 37(4), 353-361. PMID: 19553066

157. Roll, J.M., Madden, G.J., Rawson, R., & Petry, N.M. (2009). Facilitating the adoption of contingency management for the treatment of substance use disorders. Behavior Analysis in Practice, 2(1), 4-13. PMCID: PMC2854061

158. Glasner-Edwards, S., Mooney, L.J., Marinelli-Casey, P., Hillhouse, M., Ang, A., Rawson, R.A., & the Methamphetamine Treatment Project Corporate Authors. (2009). Psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug and Alcohol Review, 29, 12-20. PMID: 20078677 NIHMSID 475182

159. Mooney, L.J., Glasner-Edwards, S., Marinelli-Casey, P., Hillhouse, M., Ang, A., Hunter, J., Haning, B., Colescott, P, Ling, W., & Rawson, R.A. (2009). Health conditions in methamphetamine-dependent adults 3 years after treatment. Journal of Addiction Medicine, 3(3), 155-163. PMID: 21769012

160. Spear, S., Tillman, S., Moss, C., Gong-Guy, E., Ransom, L., & Rawson, R.A. (2009). Another way of talking about substance abuse: Substance abuse screening and brief intervention in a mental health clinic. Journal of Human Behavior in the Social Environment, 19, 959-977. PMCID: PMC3137280

161. Hasan, N.M., Loza, N., El-Dosoky, A., Hamdi, N., Rawson, R., Hasson, A.L., Shawky, M.M. (2009). Characteristics of clients with substance abuse disorders in a private hospital in Cairo, Egypt. Journal of Muslim Mental Health, 4(1), 9-15.


21

162. Sodano, R., Watson, D.W., Rataemane, S., Rataemane, L., Ntlhe, N., & Rawson, R. (2010). The substance abuse treatment workforce of South Africa. International Journal of Mental Health and Addiction, 8(4), 608-615. PMCID: PMC2965395

163. Shetty, V., Mooney, L.J., Zigler, C.M., Belin, T.R., Murphy, D., & Rawson, R. (2010). The relationship between methamphetamine use and increased dental disease. Journal of the American Dental Association, 141, 307-318. PMCID: PMC2947197

164. Gonzales, R., Mooney, L., & Rawson, R.A. (2010). The methamphetamine problem in the United States. Annual Review of Public Health, 31, 6.1-6.14. PMCID: PMC4440680

165. Rutkowski, B.A., Gallon, S., Rawson, R.A., Freese, T.E., Bruehl, A., Crèvecoeur-Macphail, D., Sugita, W., Molfenter, T., & Cotter, F. (2010). Improving client engagement and retention in treatment: The Los Angeles County experience. Journal of Substance Abuse Treatment, 39, 78-86. PMID: 20409672

166. Rawson, R.A., & Gonzales, R. (2010). Commentary on Marshall et al. (2010): Are long-term negative health consequences of methamphetamine use important to youth? Addiction, 105, 1003-1004. PMCID: PMC4074535

167. Glasner-Edwards, S., & Rawson, R. (2010). Evidence-based practices in addiction treatment: Review and recommendations for public policy. Health Policy, 97, 93-104. PMCID: PMC2951979

168. Glasner-Edwards, S., Mooney, L.J., Marinelli-Casey, P., Hillhouse, M., Ang, A., & Rawson, R.; Methamphetamine Treatment Project Corporate Authors. (2010). Anxiety disorders among methamphetamine dependent adults: Association with post-treatment functioning. American Journal on Addictions, 19(5), 385-390. PMCID: PMC3159418

169. Momtazi, S., & Rawson, R. (2010). Substance abuse among Iranian high school students. Current Opinion in Psychiatry, 23, 221-226. PMCID: PMC4479403

170. Zorick, T., Nestor, L., Miotto, K., Sugar, C., Hellemann, G., Scanlon, G., Rawson, R., & London, E.D. (2010). Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction, 105(10), 1809-1818. PMCID: PMC3071736

171. Crèvecoeur-MacPhail, D., Bellows, A., Rutkowski, B.A., Ransom, L., Myers, A.C., & Rawson, R.A. (2010). “I’ve been NIATxed”: Participants’ experience with process improvement. Journal of Psychoactive Drugs, SARC Supplement 6, 249-259. PMID: 21138201

172. Crèvecoeur-MacPhail, D., Ransom, L., Myers, A.C., Annon, J.J., Diep, N., Gonzales, R., Rawson, R.A., Viernes, J., Jr., Sugita, W., & Barger, J. (2010). Inside the black box: Measuring addiction treatment services and their relation to outcomes. Journal of Psychoactive Drugs, SARC Supplement 6, 269-276. PMID: 21138203

173. Davoudi, M., & Rawson, R.A. (2010). Screening, brief intervention, and referral to treatment (SBIRT) initiatives in California: Notable trends, challenges, and recommendations. Journal of Psychoactive Drugs, SARC Supplement 6, 239-248. PMID: 21138200

174. Herbeck, D.M., Gonzales, R., & Rawson, R.A. (2010). Performance improvement in addiction treatment: Efforts in California. Journal of Psychoactive Drugs, SARC Supplement 6, 261-268. PMID: 21138202

175. Tomás-Rosselló, J., Rawson, R.A., Zarza, M.J., Bellows, A., Busse, A., Saenz, E., Freese, T., Shawkey, M., Carise, D., Ali, R., & Ling, W. (2010). United Nations Office on Drugs and Crime International Network of Drug Dependence Treatment and Rehabilitation Resources Centres: Treatnet. Substance Abuse, 31, 251-263. PMID: 21038179

176. Galloway, G.P., Singleton, E.G., Buscemi, R., Baggott, M.J., Dickerhoof, R.M., Mendelson, J.E.; Methamphetamine Treatment Project Corporate Authors. (2010). An examination of drug craving over time in abstinent methamphetamine users. American Journal on Addictions, 19(6), 510-514. doi: 10.1111/j.1521-0391.2010.00082.x. PubMed PMID: 20958846. NIHMS228815

177. Rawson, R.A., Gonzales, R., Crèvecoeur-MacPhail, D., Urada, D., Brecht, M.-L., Chalk, M., Kemp, J., & Cunningham, M. (2011). Improving the accountability of California’s public substance abuse treatment system through the implementation of performance models. Journal of Psychoactive Drugs, 42(SARC Suppl. 6), 211-214. PMID: 21138197

178. Rutkowski, B.A., Rawson, R.A., & Freese, T.E. (2011). Editors’ introduction: Improving the addiction treatment system in California through the use of data and evidence-based practices – California Substance Abuse Research Consortium (SARC) meetings, 2009. Journal of Psychoactive Drugs, 42(SARC Suppl. 6), 207-210. PMID: 21138196


22

179. Glasner-Edwards, S., Mooney, L.J., Marinelli-Casey, P., Hillhouse, M., Ang, A., & Rawson, R.A. (2011). Bulimia nervosa among methamphetamine dependent adults: Association with outcomes three years after treatment. Eating Disorders: The Journal of Treatment and Prevention, 19(3), 259-269. PMCID: 3159413

180. Baser, O., Chalk, M., Rawson, R., & Gastfriend, D.R. (2011). Alcohol dependence treatments: Comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence. The American Journal of Managed Care, 17(Suppl. 8), S222-S234. PMID: 21761948

181. Dickerson, D., Spear, S., Marinelli-Casey, P., Rawson, R.A., Li, L., & Hser, Y.-I. (2011). American Indians/Alaska Natives and substance abuse treatment outcomes: Positive signs and continuing challenges. Journal of Addictive Diseases, 30(1), 63-74. PMCID: PMC3042549

182. Gonzales, R., Brecht, M.-L., Mooney, L., & Rawson, R.A. (2011). Prescription and over-the-counter drug treatment admissions to the California public treatment system. Journal of Substance Abuse Treatment, 40(3), 224-229. PMCID: PMC4018412

183. Gonzales, R., Ang, A., Glik, D.C., Rawson, R.A., Lee, S., Iguchi, M.Y.; Methamphetamine Treatment Project Corporate Authors. (2011). Quality of life among treatment seeking methamphetamine-dependent individuals. The American Journal on Addictions, 20(4), 366-372. PMCID: PMC4026308

184. Anderson, A.L., Li, S.-H., Biswas, K., McSherry, F., Holmes, T., Iturriaga, E., Kahn, R., Chiang, N., Beresford, T., Campbell, J., Haning, W., Mawhinney, J., McCann, M., Rawson, R., Stock, C., Weis, D., Yu, E., & Elkashef, A.M. (2012). Modafinil for the treatment of methamphetamine dependence. Drug and Alcohol Dependence, 120(1-3), 135-141. PMCID: PMC3227772

185. Elkashef, A., Kahn, R., Yu, E., Iturriaga, E., Li, S.-H., Anderson, A., Chiang, N., Ait-Daoud, N., Weiss, D., McSherry, F., Serpi, T., Rawson, R., Hrymoc, M., Weis, D., McCann, M., Pham, T., Stock, C., Dickinson, R., Campbell, J., Gorodetzky, C., Haning, W., Carlton, B., Mawhinney, J., Li, M.D., & Johnson, B.A. (2012). Topiramate for the treatment of methamphetamine addiction: A multi-center placebo-controlled trial. Addiction, 107(7), 1297-1306. PMCID: PMC3331916

186. Karno, M., Farabee, D., Brecht, M.L., & Rawson, R.A. (2012). Patient reactance moderates the effect of directive telephone counseling for methamphetamine users. Journal of Studies on Alcohol and Drugs, 73, 844–850. PMCID: PMC3410952

187. Farabee, D., Cousins, S.J., Brecht, M.-L., Antonini, V.P., Lee, A.B., Brummer, J., Hemberg, J., Karno, M., & Rawson, R.A. (2012). A comparison of four telephone-based counseling styles for recovering stimulant users. Psychology of Addictive Behavior, 27, 223-229. PMCID: PMC3500433

188. Urada, D., Schaper, E., Alvarez, L., Reilly, C., Dawar, M., Field, R., Antonini, V.P., Oeser, B.T., Crèvecoeur-MacPhail, D., & Rawson, R.A. (2012). Perceptions of mental health and substance use disorder services integration among the workforce in primary care settings. Journal of Psychoactive Drugs, 44(4), 292-298. PMID: 23210377

189. Padwa, H., Urada, D., Antonini, V.P., Ober, A., Crèvecoeur-MacPhail, D., & Rawson, R.A. (2012). Integrating substance use disorder services with primary care: The experience in California. Journal of Psychoactive Drugs, 44(4), 299-306. PMCID: PMC3664544

190. Cousins, S.J., Antonini, V.P., & Rawson, R.A. (2012). Utilization, measurement, and funding of recovery supports and services in California. Journal of Psychoactive Drugs, 44(4), 325-333. PMID: 23210381

191. Rawson, R.A., Gonzales, R., Greenwell, L., & Chalk, M. (2012). Process-of-care measures as predictors of client outcome among a methamphetamine-dependent sample at 12- and 36-month follow-ups. Journal of Psychoactive Drugs, 44(4), 342-349. PMCID: PMC4018415

192. Rutkowski, B.A., Rawson, R.A., & Freese, T.E. (2012). Editors’ introduction: The evidence for integrated care—substance use disorders, mental health and primary care: California Substance Abuse Research Consortium (SARC) meetings, 2011. Journal of Psychoactive Drugs, 44(4), 281-284. PMID: 23210375

193. Evans, E., Pierce, J., Li, L., Rawson, R., & Hser, Y.I. (2012). More alike than different: Health needs, services utilization, and outcomes of Asian American and Pacific Islander (AAPI) populations treated for substance use disorders. Journal of Ethnicity in Substance Abuse, 11(4), 318-338. PMCID: PMC3526835


23

194. Dolezal, B.A., Chudzynski, J., Storer, T.W., Abrazado, M., Penate, J., Mooney, L., Dickerson, D., Rawson, R.A., & Cooper, C.B. (2013). Eight weeks of exercise training improves fitness measures in methamphetamine-dependent individuals in residential treatment. Journal of Addiction Medicine, 7(2), 122-128. PMCID: PMC3617407

195. Rawson, R.A., Rataemane, S., Rataemane, L., Ntlhe, N., Fox, R.S., McCuller, J., & Brecht, M.-L. (2013). Dissemination and implementation of cognitive behavioral therapy for stimulant dependence: A randomized trial comparison of 3 approaches. Substance Abuse, 34(2), 108-117. PMCID: PMC3625982

196. Farabee, D., McCann, M., Brecht, M.-L, Cousins, S.J., Antonini, V.P., Lee, A.B., Hemberg, J., Karno, M., & Rawson, R.A. (2013). An analysis of relapse prevention factors and their ability to predict sustained abstinence following treatment completion. American Journal on Addictions, 22(3), 206-211. PMID: 23617860 doi: 10.1111/j.1521-0391.2012.00328.x. PMCID: PMC4437594

197. Ma, J.Z., Johnson, B.A., Yu, E., Weiss, D., McSherry, F., Saadvandi, J., Iturriaga, E., Ait-Daoud, N., Rawson, R.A., Hrymoc, M., Campbell, J., Gorodetzky, C., Haning, W., Carlton, B., Mawhinney, J., Weis, D., McCann, M., Pham, T., Stock, C., Dickinson, R., Elkashef, A., & Li, M.D. (2013). Fine-grain analysis of the treatment effect of topiramate on methamphetamine addiction with latent variable analysis. Drug and Alcohol Dependence, 130(1-3), 45-51. PMID: 23142494

198. Glasner-Edwards, S., Mooney, L., Ang, A., Hillhouse, M., & Rawson, R. (2013). Does posttraumatic stress disorder (PTSD) affect post-treatment methamphetamine use? Journal of Dual Diagnosis, 9(2), 123-128. doi:10.1080/15504263.2013.779157 PMCID: PMC3779468

199. Rawson, R.A. (2013). Current research on the epidemiology, medical and psychiatric effects, and treatment of methamphetamine use. Journal of Food and Drug Analysis, 21(4), S77-S81. doi: 10.1016/j.jfda.2013.09.039 PMCID: PMC4158843

200. Hser, Y.-I., Chang, L., Wang, G.-J., Li, M.D., Rawson, R., Shoptaw, S., Normand, J., & Tai, B. (2013). Capacity building and collaborative research on cross-national studies in the Asian region. Journal of Food and Drug Analysis, 21(4), S117-S122. http://dx.doi.org/10.1016/j.jfda.2013.09.048 PMCID: PMC3931525

201. Giang, L.M., Ngoc, L.B., Hoang, V.H., Mulvey, K., & Rawson, R.A. (2013). Substance use disorders and human immunodeficiency virus in Vietnam since Doi Moi (Renovation): An overview. Journal of Food and Drug Analysis, 21(4), S42-S45. PMCID: PMC 4179236 http://dx.doi.org/10.1016/j.jfda.2013.09.032

202. Mooney, L.J., Cooper, C., London, E.D., Chudzynski, J., Dolezal, B., Dickerson, D., Brecht, M.-L., Peñate, J., & Rawson, R.A. (2013). Exercise for methamphetamine dependence: Rationale, design, and methodology. Contemporary Clinical Trials, 37(1), 139-147. doi: 10.1016/j.cct.2013.11.010. PMCID: PMC4431553

203. Abolmaged, S., Kodera, A., Okasha, T., Gawad, T., & Rawson, R. (2013). Tramadol use in Egypt: Emergence of a major new public health problem. Canadian Journal of Addiction Medicine, 4(1), 5.

204. Dolezal, B.A., Chudzynski, J., Dickerson, D., Mooney, L., Rawson, R.A., Garfinkel, A., Cooper, C.B. (2014). Exercise training improves heart rate variability after methamphetamine dependency. Medicine and Science in Sports and Exercise, 46(6), 1057-1066. PMCID: PMC3999306

205. Urada, D., Teruya, C., Gelberg, L., & Rawson, R. (2014). Integration of substance use disorder services with primary care: Health center surveys and qualitative interviews. Substance Abuse Treatment, Prevention, and Policy, 9(1), 15. doi:10.1186/1747-597X-9-15 PMCID: PMCID 3978198

206. Rawson, R.A., Rieckmann, T., & Gust, S.W. (2014). Addiction science: A rationale and tools for a public health response to drug abuse. Public Health Reviews, 35(2). http://www.publichealthreviews.eu/show/f/147 NIHMSID 644383

207. Al-Hemiary, N.J., Al-Diwan, J.K., Hasson, A.L., & Rawson, R.A. (2014). Drug and alcohol use in Iraq: Findings of the inaugural Iraqi Community Epidemiological Workgroup. Substance Use & Misuse, 49(13), 1759-1763. DOI: 10.3109/10826084.2014.913633. PMCID: PMC4431571

208. Urada, D., Rawson, R.A., & Onuki, M. (2014). Peace building through a substance use conference structured on peace psychology principles. Peace and Conflict: Journal of Peace Psychology, 20(1), 84-94. http://dx.doi.org/10.1037/a0035579


24

209. Radfar, S.R., & Rawson, R.A. (2014). Current research on methamphetamine: Epidemiology, medical and psychiatric effects, treatment, and harm reduction efforts. Addiction & Health, 6(3-4), 146-154. http://ahj.kmu.ac.ir/index.php/ahj/article/view/187/229 PMCID: PMC4354220.

210. Nosyk, B., Li, L., Evans, E., Urada, D., Huang, D., Wood, E., Rawson, R., & Hser, Y.-I. (2014). Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, US: 1991-2012. Drug and Alcohol Dependence, 143, 149-157. doi: 10.1016/j.drugalcdep.2014.07.020 PMCID: PMC4484858

211. Nosyk, B., Li, L., Evans, E., Urada, D., Huang, D., Wood, E., Rawson, R., & Hser, Y.-I. (2015). Erratum to “Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, US: 1991–2012” [Drug Alcohol Depend. 143 (2014) 149–157]. Drug and Alcohol Dependence, 148, 230-232. doi: http://dx.doi.org/10.1016/j.drugalcdep.2014.10.018

212. Radfar, S.R., Sedaghat, A., Banihashemi, A.T., Gouya, M., & Rawson, R.A. (2014). Behaviors influencing human immunodeficiency virus transmission in the context of positive prevention among people living with HIV/acquired immunodeficiency syndrome in Iran: A qualitative study. International Journal of Preventive Medicine, 5(8), 976-983. PMCID: PMC4258663

213. Messina, N., Jeter, K., Marinelli-Casey, P., West, K., Rawson, R.A. (2014). Children exposed to methamphetamine use and manufacture. Child Abuse & Neglect, 38(11), 1872-1883. doi: 10.1016/j.chiabu.2006.06.009. PMCID: PMC3029499

214. Rawson, R.A., Chudzynski, J., Gonzales, R., Mooney, L., Dickerson, D., Ang, A., Dolezal, B., & Cooper, C.B. (2015). The impact of exercise on depression and anxiety symptoms among abstinent methamphetamine-dependent individuals in a residential treatment setting. Journal of Substance Abuse Treatment, 57, 36-40. doi:10.1016/j.jsat.2015.04.007. PMC4560957

215. Haglund, M., Ang, A., Mooney, L., Gonzales, R., Chudzynski, J., Cooper, C.B., Dolezal, B.A., Gitlin, M., & Rawson, R.A. (2015). Predictors of depression outcomes among abstinent methamphetamine-dependent individuals exposed to an exercise treatment. American Journal on Addictions, 24(3), 246-251. doi: 10.1111/ajad.12175.

216. Rawson, R.A., Woody, G., Kresina, T.F., & Gust, S. (2015). The globalization of addiction research: Capacity building mechanisms and selected examples. Harvard Review of Psychiatry, 23(2), 147-156. PMCID: PMC4356020 doi: 10.1097/HRP.0000000000000067

217. Cousins, S.J. , Denering, L., Crèvecoeur-MacPhail, D., Viernes, J., Sugita, W., Barger, J., Kim, T., Weismann, S., & Rawson, R.A. (2016). A demonstration project implementing extended-release naltrexone in Los Angeles County. Substance Abuse, 37(1), 54-62. DOI: 10.1080/08897077.2015.1052868

218. Rawson, R.A., Chudzynski, J., Mooney, L., Gonzales, R., Ang, A., Dickerson, D., Penate, J., Salem, B.A., Dolezal, B., & Cooper, C.B. (2015). Impact of an exercise intervention on methamphetamine use outcomes post-residential treatment care. Drug and Alcohol Dependence, 156, 21-28. PMCID: PMC4633370. doi: 10.1016/j.drugalcdep.2015.08.029.

219. Glasner-Edwards, S., Mooney, L., Ang., A., Garneau, H.C., Hartwell, E.E., Brecht, M.-L., Rawson, R.A. (2015). Mindfulness based relapse prevention improves stimulant use among adults with major depression and generalized anxiety disorder. Drug and Alcohol Dependence, 156, e80. doi: http://dx.doi.org/10.1016/j.drugalcdep.2015.07.1135

220. Robertson, C.L., Ishibashi, K., Chudzynski, J., Mooney, L.J., Rawson, R.A., Dolezal, B.A., Cooper, C.B., Brown, A.K., Mandelkern, M.A., & London, E.D. (2016). Effect of exercise training on striatal dopamine D2/D3 receptors in methamphetamine users during behavioral treatment. Neuropsychopharmacology, 41(6), 1629-1636. doi: 10.1038/npp.2015.331. PMCID: PMC4832026 [Available May 1, 2017]

221. Cousins, S.J., Radfar, S.R., Crèvecoeur-MacPhail, D., Ang, A., Darfler K., & Rawson, R.A. (2016). Predictors of continued use of extended-release naltrexone (SR-NTX) for opioid dependence: An analysis of heroin and non-heroin opioid users in Los Angeles County. Journal of Substance Abuse Treatment, 63, 66–71. doi: http://dx.doi.org/10.1016/j.jsat.2015.12.004


25

222. Kohno, M., Okita, K., Morales, A.M., Robertson, C.L., Dean, A.C., Ghahremani, D.G., Saab, F.W., Rawson, R.A., Mandelkern, M.A., Bilder, R.M., & London, E.D. (2016). Midbrain functional connectivity and ventral striatal dopamine D2-type receptors: Link to impulsivity in methamphetamine users. Molecular Psychiatry. doi: 10.1038/mp.2015.223 [Epub ahead of print]. PMCID: PMC4970974

223. Radfar, S.R., Cousins, S.J., Shariatirad, S., Noroozi, A., & Rawson, R.A. (2016). Methamphetamine use among patients undergoing methadone maintenance treatment in Iran; a threat for harm reduction and treatment strategies: A qualitative study. International Journal of High Risk Behaviors & Addiction. doi: 10.5812/ijhrba.30327 [Epub ahead of print].

224. Glasner-Edwards, S., Patrick, K., Ybarra, M., Reback, C.J., Rawson, R.A, Chokron Garneau, H, Chavez, K., & Venegas, A. (2016). A cognitive behavioral therapy-based text messaging intervention versus medical management for HIV-infected substance users: Study protocol for a pilot randomized trial. JMIR Research Protocols, 5(2), e131. PMCID: 4938885 doi: 10.2196/resprot.5407

225. Glasner-Edwards, S., Mooney, L.J., Ang, A.C., Chokr, H., Hartwell, E.M., Brecht, M.-L., & Rawson, R. A. (2016). Mindfulness-based relapse prevention for stimulant dependent adults: A pilot randomized clinical trial. Mindfulness. doi:10.1007/s12671-016-0586-9

226. Padwa, H., Urada, D., Gauthier, P., Rieckmann, T., Hurley, B., Crèvecoeur-MacPhail, D., & Rawson, R.A. (2016). Organizing publicly funded substance use disorder treatment in the United States: Moving toward a service system approach. Journal of Substance Abuse Treatment, 69, 9-18. doi: http://dx.doi.org/10.1016/j.jsat.2016.06.010

227. Miotto, K., Cho, A.K., Khalil, M.A., Blanco, K., Sasaki, J.D., & Rawson, R.A. (2016). Trends in tramadol: Pharmacology, metabolism, and misuse. Anesthesia & Analgesia. doi: 10.1213/ANE.0000000000001683 [Epub ahead of print, Nov. 17]

228. Glasner-Edwards, S., Hartwell, E.E., Mooney, L., Ang, A., Garneau, H.C., Brecht, M.-L., & Rawson, R.A. (2016). Changes in stress reactivity among stimulant dependent adults after treatment with mindfulness based relapse prevention: Results from a pilot randomized clinical trial. Journal of Addiction Research & Therapy. doi:10.4172/2155-6105.1000298

RRESEARCH PAPERS – PEER REVIEWED (IN PRESS) 1. Rawson, R.A., & Clark, N. (in press). Inter country meeting on strengthening the public health response to

substance use. Interventions for the management of substance use disorders: Review and recommendations. Eastern Mediterranean Health Journal.

2. Wolitzky-Taylor, K., Rawson, R., Ries, R., Roy-Byrne, P. & Craske, M.G. (in press). Adaptation of Coordinated Anxiety Learning and Management (CALM) for comorbid anxiety and substance use disorders: Delivery of evidence-based treatment for anxiety in addictions treatment centers. Implementation Science (Suppl).

C. RESEARCH PAPERS – PEER REVIEWED (SUBMITTED)

1. Al-Hemiery, N., Dabbagh, R., Hashim, M.T., Al-Hasnawi, S., Abutiheen, A., Abdulghani, E.A., Al-Diwan,

J.K., Kak, N., AlMossawi, H., Maxwell, J.C., Brecht, M.-L., Antonini, V., Hasson, A., & Rawson, R.A. (in submission). Self-reported substance use in Iraq: Findings from the Iraqi National Household Survey on Alcohol and Drug Use, 2014. Lancet

2. Miotto, K., Cho, A., Khalil, M., Blanco, K., & Rawson, R. (in submission). Will tramadol become the next Vicodin? Journal of Internal Medicine.

3. Le, G.M., Nguyen, H., Tran, H., Bart, G., Rieckmann, T., Duy, C., Nguyen, H.T., Nguyen, S., Darfler, K., & Rawson, R.A. (in submission). Alcohol and drug use among patients receiving HIV services in Hanoi, Vietnam.


26

4. Garneau, H.C., Venegas, A., Rawson, R.A., & Glasner-Edwards, S. (in submission). Barriers to initiation of Vivitrol among HIV-infected adults with alcohol use disorders. Journal of Substance Abuse Treatment.

5. Crèvecoeur-MacPhail, D., Cousins, S.J., Denering, L., & Rawson, R.A. (in submission). Effectiveness of long-acting naltrexone to reduce alcohol cravings and use behaviors during treatment and at follow-up. Journal of Substance Abuse Treatment.

LETTERS TO THE EDITOR

1. Al Hemiary, N., Al-Diwan, J., Hasson, A., Rawson, R.A. (2012). Report on drug and alcohol use in Iraq: The inaugural meeting of the Community Epidemiology Work Group. International Psychiatry, 9(4), 102.

2. Gonzales, R., Marinelli-Casey, P., Hillhouse, M., Hunter, J., Rawson, R.A., Mooney, L., & Ang, A. (2008). Hepatitis A and B infection among methamphetamine-dependent users. Journal of Substance Abuse Treatment, 35(3), 351-352 [Letter to the Editor]. PMID: 18640808

BOOKS AND MANUALS

1. Rawson, R.A., Obert, J.L., McCann, M.J., Smith, D.P., & Scheffey, E.H. (1989). The neurobehavioral treatment manual. Beverly Hills, CA: Matrix.

2. Rawson, R.A., Obert, J.L., McCann, M.J., & Ling, W. (1991). The Matrix Model of outpatient treatment for alcohol abuse and dependency. Beverly Hills, CA: Matrix.

3. McCann, M.J., Rawson, R.A., Obert, J.L., & Hasson, A.J. (1992). Treatment of opiate addiction using methadone: A counselor manual. CSAT TAP #7. Rockville, MD: U.S. Department of Health and Human Services.

4. Rawson, R.A., Obert, J.L., McCann, M.J., & Ling, W. (1992). The Matrix Model for the treatment of opiate addiction with naltrexone. Beverly Hills, CA: Matrix.

5. Shoptaw, S., Rawson, R.A., Blum, M., & Obert, J.L. (1994). Outpatient drug treatment manual for HIV-positive substance abusers. Beverly Hills, CA: Matrix Institute on Addictions.

6. Rawson, R.A. (1999). TIP 33: Treatment for stimulant abuse disorders: Treatment Improvement Protocol (TIP) Series 33. Center for Substance Abuse Treatment (CSAT). (Chair, CSAT Consensus panel). Rockville, MD: U.S. Department of Health and Human Services.

7. Sorensen, J.L., Rawson, R., Guydish, J., & Zweben, J. (Eds.) (2002). Drug abuse treatment through collaboration. Washington, DC: American Psychological Association

8. Isralowitz, R. Afifi, M., & Rawson, R. (Eds.) (2002). Drug problems: Cross-cultural policy and program development. Westport, CT: Greenwood Publishing.

9. McCann, M.J., Obert, J.L., Marinelli-Casey, P., & Rawson, R.A. (2005) Meth: The basics. Center City, MN: Hazelden.

10. Rawson, R.A. (2006). Methamphetamine: New knowledge, new treatments. Center City, MN: Hazelden.

11. Roll, J., Rawson, R.A, Shoptaw, S., & Ling, W. (Eds.) (2009). Methamphetamine addiction: From basic science to treatment. New York: Guilford Press.


27

BOOKS and MANUALS (IN PRESS)

BOOK CHAPTERS

1. Callahan, E.J., & Rawson, R.A. (1978). Outcome behavioral assessment of narcotic addiction. In M. Sobell & L. Sobell (Eds.) Current evaluation of alcohol and drug treatment. New York: Pergammon Press.

2. Callahan, E.J., & Rawson, R.A. (1979). Preserving the rights of narcotic addict clients. In J.T. Hannah, H.P. Clark & W.P. Christian (Eds.), Preservation of clients rights: Systems for the treatment and protection of persons receiving psychological, medical and educational services. New York, Free Press.

3. Rawson, R.A. (1995). Is psychotherapy effective for substance abuse? In A.M. Washton (Ed.), Psychotherapy and substance abuse: A practitioner’s handbook (pp. 55-75). New York: Guilford Press.

4. Ling, W., Compton, M., Rawson, R.A., & Wesson, D. (1996). Neuropsychiatry of alcohol and drug abuse. In B.S. Fogel & R.B. Schiffer (Eds.), Neuropsychiatry: A comprehensive textbook. Baltimore, MD: Williams & Wilkins.

5. Washton, A.M., & Rawson, R.A. (1998). Substance abuse treatment under managed care. In M. Galanter & H. Kleber (Eds.), Textbook of substance abuse treatment. Washington DC: APA Press.

6. Rawson, R.A., McCann M.J., Huber A., & Shoptaw, S. (1999). Contingency management and relapse prevention as stimulant abuse interventions. In S.T. Higgins & K. Silverman (Eds.), Motivating behavior change among illicit-drug abusers: Contemporary research on contingency management interventions (pp. 57-74). Washington DC: APA Press.

7. Rawson, R.A., & Obert, J.L. (2002). Relapse prevention groups. In D.W. Brook & H.I. Spitz (Eds.), Group psychotherapy of substance abuse. Washington, DC: APA Press.

8. Obert, J., Borkin, S., Degani, H., & Rawson, R.A. (2002). Outpatient substance abuse treatment using scientifically supported treatment manuals: Implementation in the Palestinian Authority and Israel. In R. Isralowitz, M. Afifi, & R. Rawson (Eds.), Drug problems: Cross-cultural policy and program development. Westport, CT: Greenwood Publishing.

9. Isralowitz, R., Afifi, M., & Rawson, R. (2002). Overview of cooperative substance abuse activities in the Middle East. In R. Isralowitz & R. Rawson (Eds.), Drug problems: Cross-cultural policy and program development. Westport, CT: Greenwood Publishing.

10. Rawson, R., Hasson, A. Afifi, M., & Isralowitz, R. (2002). Middle East Drug Use Watch (MEDUW): A tri-lateral system to measure the type and extent of psychoactive substance use in Palestinian and Israeli communities. In R. Isralowitz, M. Afifi & R. Rawson (Eds.), Drug problems: Cross-cultural policy and program development. Westport, CT: Greenwood Publishing.

11. Rawson, R.A., & Obert, J.L. (2002). The substance abuse treatment system in the US. What is it? What does it do? Myths and misconceptions. In J.E. Zweben & S. Lambert (Eds.), Occupational medicine: A state of the art review (pp. 1-21). Philadelphia, PA: Hanley and Belfus.

12. Castro, F.G., Obert, J.L., Rawson, R.A., Valdez, C., & Denne, R. (2002). Toward the development of culturally competent treatments. In G. Bernal, J.E. Trimble, A.K. Burlew & F.T.L. Leong (Eds.), Handbook of racial and ethnic minority psychology. Thousand Oaks, CA: Sage.

13. Sorensen, J.L., Guydish, J., Rawson, R., & Zweben, J. (2003). Introduction: The need for research-practice collaboration. In J. Sorensen, R.A. Rawson, J. Guydish & J. Zweben (Eds.), Drug abuse treatment through collaboration: Practice and research partnerships that work. Washington, DC: American Psychological Association.

14. Ling, W., Rawson, R.A., Anglin, M..D. (2003). Agonist pharmacotherapies for opiate dependence: Comparing the development and implementation of methadone and LAAM. In J. Sorensen, R.A. Rawson, J. Guydishc & J. Zweben (Eds.), Drug abuse treatment through collaboration: Practice and research collaborations that work. Washington, DC: American Psychological Association.


28

15. Rawson, R.A., Sodano, R., & Marinelli-Casey, P. (2003). Alcohol use and the workplace. In B. Johnson, P. Ruiz, & M. Galanter (Eds.), Handbook of alcoholism treatment. New York: Lippincott.

16. Obert, J.L., Weiner, A., Stimpson, J., & Rawson, R.A. (2004). Treating substance use disorders. In R. Coombs (Ed.), Handbook of addictive disorders (pp. 94-125). Hoboken, NJ: John Wiley & Sons.

17. Rawson, R.A., Sodano, R., & Hillhouse, M. (2005). Assessment of amphetamine use disorders. In D.M. Donovan & G.A. Marlatt (Eds.), Assessment of addictive behaviors (pp. 185-214). New York: Guilford.

18. Jaffe, J.A., Rawson, R.A., & Ling, W.L. (2005). Cocaine. In B.J. Sadock & V.A. Sadock (Eds.), Kaplan and Sadock’s comprehensive textbook of psychiatry (pp. 1220-1237). Baltimore, MD: Lippincott.

19. Jaffe, J.A., Ling, W., & Rawson, R.A. (2005). Amphetamines. In B.J. Sadock & V.A. Sadock (Eds.), Kaplan and Sadock’s comprehensive textbook of psychiatry (pp.1188-1200). Baltimore, MD: Lippincott.

20. Carroll, K.M., & Rawson, R.A. (2005). Relapse prevention approaches for stimulant dependent individuals. In G.A. Marlatt & D. Donovan (Eds.), Relapse prevention approaches for the treatment of substance use disorders. New York: Guilford.

21. Rawson, R.A. (2006). Research strategies to test behavioral/psychotherapy treatments for substance use disorders: Several examples. In N. Loza & A. El-Dosoky (Eds.), Current addiction treatment issues in the Middle East. Cairo, Egypt: United Nations Office of Drugs and Crime Regional Office Publication.

22. Rawson, R.A. (2006). Intensive outpatient treatment for substance use disorders: The Matrix Model. In N. Loza & A. El-Dosoky (Eds.), Current addiction treatment issues in the Middle East. Cairo, Egypt: United Nations Office of Drugs and Crime Regional Office Publication.

23. Rawson, R.A. (2006). Naltrexone for the treatment of opiate addiction. In N. Loza & A. El-Dosoky (Eds.), Current addiction treatment issues in the Middle East. Cairo, Egypt: United Nations Office of Drugs and Crime Regional Office Publication.

24. Rawson, R.A. (2006). The Matrix Model: An intensive structured outpatient approach. In S. Trad (Ed.), Proceedings of the Conference in Beirut Lebanon titled “New Perspectives on the Prevention and Treatment of Addictions.” Beirut, Lebanon: Skoun.

25. Maxwell, J.C., Rutkowski, B.A., & Rawson, R.A. (2007). Substance abuse epidemiology in the United States: A review of indicator data. In A. Kalechstein & W.G. van Gorp (Eds.), Neuropsychology and substance use: State-of-the-art and future directions (pp.1-39). New York: Taylor & Francis.

26. Rawson, R.A., & Ling, W.L. (2008). Methamphetamine abuse and dependence: Current treatments. In M. Galanter & H. Kleber (Eds.), Textbook of substance abuse treatment. Arlington, VA: American Psychiatric Association Press.

27. Mooney, L.J., Glasner-Edwards, S., Rawson, R.A., & Ling, W. (2009) Medical effects of methamphetamine use. In J.M. Roll, R.A. Rawson, W. Ling, & S. Shoptaw (Eds.), Methamphetamine addiction: From basic science to treatment (pp. 117-142). New York: Guilford Press.

28. Roll, J., Rawson, R., Shoptaw, S., & Ling, W. (2009). Introduction. In J.M. Roll, R.A. Rawson, W. Ling, & S. Shoptaw (Eds.), Methamphetamine addiction: From basic science to treatment (pp. 1-5). New York: Guilford Press.

29. Shoptaw, S., Rawson, R.A., Worley, M., Lefkowith, S., & Roll, J.M. (2009). Psychosocial and behavioral treatment of methamphetamine dependence. In J.M. Roll, R.A. Rawson, W. Ling, & S. Shoptaw (Eds.), Methamphetamine addiction: From basic science to treatment (pp. 185–201). New York: Guilford Press.

30. Rawson, R.A. (2009). Treatments for methamphetamine dependence: Contingency management and the Matrix Model. In R. Pates & D. Riley (Eds.), Interventions for amphetamine misuse (pp. 83-100). Oxford, UK. Wiley Blackwell.

31. Rawson, R.A. (2011, September). Building an addiction workforce in the Middle East: A counselor training program partnership between Kasr Al-Ainy and UCLA. In Public Health in the Middle East: Building a Healthy Future (pp. 21-25). Washington, DC: Middle East Institute.


29

32. Rawson, R.A., Gonzales, R., & Ling, W. (2011). Clinical aspects of methamphetamine. In B.A. Johnson (Ed.), Addiction medicine: Science and Practice (Vol. 1, pp. 495-510). New York: Springer.

33. Ling, W., Mooney, L., & Rawson, R.A. (2013). Amphetamine-type stimulants. In B.S. McCrady & E.E. Epstein (Eds.), Addictions: A comprehensive guidebook (2nd Edition, Chapter 8). New York: Oxford University Press.

34. Gonzales, R., Brecht, L., & Rawson, R.A. (2013). Adolescent substance abuse treatment outcomes. In R. Rosner (Ed.), Clinical handbook of adolescent addiction (pp. 267-271). Oxford, UK: Wiley-Blackwell.

35. Rawson, R.A., Ling, W., & Mooney, L.J. (2015). Clinical management: Methamphetamine. In Galanter, M., Kleber, H.D., & Brady, K. (Eds.), The American Psychiatric Publishing textbook of substance abuse treatment (5th Edition). Arlington, VA: American Psychiatric Publishing.

36. Momtazi, S., Noroozi, A., & Rawson, R.A. (2015). An overview of Iran drug treatment and harm reduction programs. In N. el-Guebaly, G. Carrà, & M. Galanter (Eds.), Textbook of addiction treatment: International perspectives (pp. 543-554). Milan: Springer.

37. Farabee, D., Rawson, R.A., & Gawad, T.A. (2015). Treatment in criminal justice settings. In N. el-Guebaly, G. Carrà, & M. Galanter (Eds.), Textbook of addiction treatment: International perspectives (pp. 1129-1144). Milan: Springer.

38. Rawson, R.A., Rieckmann, T., & Capoccia, V. (2015). Opportunities for addiction service system development: Case studies from Vietnam, Lebanon and United Arab Emirates. In N. el-Guebaly, G. Carrà, & M. Galanter (Eds.), Textbook of addiction treatment: International perspectives (pp. 1189-1197). Milan: Springer.

39. Obert, J., McCann, M., & Rawson, R.A. (2015). Development and dissemination of the Matrix Model of intensive outpatient treatment. In N. el-Guebaly, G. Carrà, & M. Galanter (Eds.), Textbook of addiction treatment: International perspectives (pp. 691-971). Milan: Springer.

40. Mooney, L.J., Cooper, C.B., London, E.D., Chudzynski, J., & Rawson, R.A. (2015). Exercise for substance use disorders. In N. el-Guebaly, G. Carrà, & M. Galanter (Eds.), Textbook of addiction treatment: International perspectives (pp. 973-986). Milan: Springer.

41. Rawson, R.A., & Galanter, M. (2015). Behavioural approaches: An introduction. In N. el-Guebaly, G. Carrà, & M. Galanter (Eds.), Textbook of addiction treatment: International perspectives (pp. 775-778). Milan: Springer.

42. Nathan, P.E., Zweben, J.E., & Rawson, R.A. (2016). Substance use disorders. In J.C. Norcross, G.R. VandenBos, D.K. Freedheim, & N. Pole (Eds.), APA handbook of clinical psychology: Psychopathology and health (Vol. 4, pp. 295-320). Washington, DC: American Psychological Association.

DVDs A. EDUCATIONAL and DOCUMENTARY DVDs

1. Freese, T. (Principle Investigator), Rawson, R (Project Advisor). (2008). Meth Inside Out DVD Series. United States: Eyes of the World Media Group.

2. Rawson, R. (Expert Panel). (2006) “Understanding Relapse” HBO: Addiction. United States: Home Box Office

Incorporated.

rawson cv june 10, 2017 - contentmanager.med.uvm.edu

Documents